FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Alexander Eggermont

Research Profile

Procedures

Disorders

Chemicals & Drugs

Anatomy

Extremities

Living Beings

Rats

Concepts & Ideas

Co-author Network

Publications

TOP 3
Timo L M ten Hagen; Sandra T van Tiel; Ernst A de Bruijn; Gisela aan de Wiel-Ambagtsheer; Simon L Goodman; Matthias Grell; Michael Meyring; Curzio Ruegg; Ann L B Seynhaeve; Alexander M M Eggermont
The αVβ3/αVβ5 integrin inhibitor cilengitide augments tumor response to melphalan isolated limb perfusion in a sarcoma model.
Li Li; Timo L M ten Hagen; Gerard C van Rhoon; Jeremy Yatvin; Michiel Bolkestein; Alexander M M Eggermont; Astrid Gasselhuber; Dieter Haemmerich; Gerben A Koning
Improved intratumoral nanoparticle extravasation and penetration by mild hyperthermia.
Steven J O'Day; Caroline Robert; Jacob Schachter; Alessandro Testori; Selma Ugurel; Vojo Vukovic; Richard Kefford; Joelle Lufkin; Jacek Mackiewicz; Laurent Mortier; Safi Bahcall; Vanna Chiarion-Sileni; Frances Collichio; Alexander M M Eggermont; Philip Friedlander; Claus Garbe; Jean Jacques Grob; Wei Guo; Axel Hauschild
Final results of phase III SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanoma.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Alexander Eggermont (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Timo L M ten Hagen; Sandra T van Tiel; Ernst A de Bruijn; Gisela aan de Wiel-Ambagtsheer; Simon L Goodman; Matthias Grell; Michael Meyring; Curzio Ruegg; Ann L B Seynhaeve; Alexander M M Eggermont
The αVβ3/αVβ5 integrin inhibitor cilengitide augments tumor response to melphalan isolated limb perfusion in a sarcoma model.
International journal of cancer. Journal international du cancer 2013;132(11):2694-704.
2013: Li Li; Timo L M ten Hagen; Gerard C van Rhoon; Jeremy Yatvin; Michiel Bolkestein; Alexander M M Eggermont; Astrid Gasselhuber; Dieter Haemmerich; Gerben A Koning
Improved intratumoral nanoparticle extravasation and penetration by mild hyperthermia.
Journal of controlled release : official journal of the Controlled Release Society 2013;167(2):130-7.
2013: Steven J O'Day; Caroline Robert; Jacob Schachter; Alessandro Testori; Selma Ugurel; Vojo Vukovic; Richard Kefford; Joelle Lufkin; Jacek Mackiewicz; Laurent Mortier; Safi Bahcall; Vanna Chiarion-Sileni; Frances Collichio; Alexander M M Eggermont; Philip Friedlander; Claus Garbe; Jean Jacques Grob; Wei Guo; Axel Hauschild
Final results of phase III SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(9):1211-8.
2013: Ninos Ayez; Jacobus W A Burger; Johannes H W de Wilt; Alexander M M Eggermont; Dirk J Grunhagen; Anne E van der Pool; Cornelis Verhoef
Long-term results of the "liver first" approach in patients with locally advanced rectal cancer and synchronous liver metastases.
Diseases of the colon and rectum 2013;56(3):281-7.
2013: Augustinus P T van der Ploeg; Cornelis Verhoef; A C J van Akkooi; Alexander M M Eggermont
Completion lymph node dissection after a positive sentinel node: no longer a must?
Current opinion in oncology 2013;25(2):152-9.
2013: Michele Maio; Caroline Robert; Anna M Di Giacomo; Alexander M M Eggermont
Update on the role of ipilimumab in melanoma and first data on new combination therapies.
Current opinion in oncology 2013;25(2):166-72.
2013: Jill A van der Zee; Bilyana M Dicheva; Alexander M M Eggermont; Wim C J Hop; Gerben A Koning; Ann L B Seynhaeve; Timo L M ten Hagen; Herman van Dekken; Casper H J van Eijck
Bcl-2 associated anthanogen-1 (Bag-1) expression and prognostic value in pancreatic head and periampullary cancer.
European journal of cancer (Oxford, England : 1990) 2013;49(2):323-8.
2013: Ninos Ayez; J W A Burger; Roy S Dwarkasing; Alexander M M Eggermont; Joost J M E Nuyttens; Wijnand J Alberda; François E J A Willemssen; Cornelis Verhoef
Is restaging with chest and abdominal CT scan after neoadjuvant chemoradiotherapy for locally advanced rectal cancer necessary?
Annals of surgical oncology 2013;20(1):155-60.
2012: Anne E M van der Pool; Joanne Verheij; Alexander M M Eggermont; Jan N M Ijzermans; Hendrick A Marsman; Fibo J Ten Kate; Cornelis Verhoef
Effect of bevacizumab added preoperatively to oxaliplatin on liver injury and complications after resection of colorectal liver metastases.
Journal of surgical oncology 2012;106(7):892-7.
2012: Remco van Horssen; Alexander M M Eggermont; Antoinette Hollestelle; Joost A P Rens; Mieke Schutte; Timo L M ten Hagen
E-cadherin promotor methylation and mutation are inversely related to motility capacity of breast cancer cells.
Breast cancer research and treatment 2012;136(2):365-77.
2012: Alexander M M Eggermont; Gaetan de Schaetzen; Reinhard Dummer; Wim H J Kruit; Jeremy Marsden; Poulam M Patel; Cornelis J A Punt; Caroline Robert; François Salès; mario santinami; Dirk Schadendorf; Alan Spatz; Stefan Suciu; Alessandro Testori; Ulrich Keilholz
Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(31):3810-8.
2012: A C J van Akkooi; Martin G Cook; Alexander M M Eggermont
Increased sampling will lead to an increase in detection, but is it clinically relevant? Reply letter regarding: "Treatment influencing down-staging in EORTC Melanoma Group sentinel node histological protocol compared with complete step-sectioning: a national multicentre study" by Riber-Hansen et al.
European journal of cancer (Oxford, England : 1990) 2012;48(15):2488-9; author reply 2486-7.
2012: Arjen Joosse; Ulrich R Kleeberg; Ferdy Lejeune; Tamar Nijsten; Stefan Suciu; Jan Willem W Coebergh; Sandra Collette; Alexander M M Eggermont; Esther de Vries
Superior outcome of women with stage I/II cutaneous melanoma: pooled analysis of four European Organisation for Research and Treatment of Cancer phase III trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(18):2240-7.
2012: Jan P Deroose; Alexander M M Eggermont; Albertus N van Geel; Jacobus W A Burger; Cornelis Verhoef
Isolated limb perfusion with TNF-alpha and melphalan for distal parts of the limb in soft tissue sarcoma patients.
Journal of surgical oncology 2012;105(6):563-9.
2012: Ninos Ayez; Jeroen de Jonge; Alexander M M Eggermont; Jan N M Ijzermans; Zarina S Lalmahomed; Kees van Montfort; Cornelis Verhoef
Outcome of microscopic incomplete resection (R1) of colorectal liver metastases in the era of neoadjuvant chemotherapy.
Annals of surgical oncology 2012;19(5):1618-27.
2012: Monica Arnedos; Benjamin Besse; Fabrice André; Françoise Farace; Ludovic Lacroix; Caroline Robert; Jean Charles Soria; Alexander M M Eggermont
The challenge to bring personalized cancer medicine from clinical trials into routine clinical practice: the case of the Institut Gustave Roussy.
Molecular oncology 2012;6(2):204-10.
2012: Alexander M M Eggermont; Vladimir Lazar; Alan Spatz; Caroline Robert
Is ulceration in cutaneous melanoma just a prognostic and predictive factor or is ulcerated melanoma a distinct biologic entity?
Current opinion in oncology 2012;24(2):137-40.
2012: Alexander M M Eggermont; Caroline Robert
Melanoma in 2011: a new paradigm tumor for drug development.
Nature reviews. Clinical oncology 2012;9(2):74-6.
2012: Jan P Deroose; Alexander M M Eggermont; Albertus N van Geel; Jacobus W A Burger; Johannes H W de Wilt; Cornelis Verhoef
20 years experience of TNF-based isolated limb perfusion for in-transit melanoma metastases: TNF dose matters.
Annals of surgical oncology 2012;19(2):627-35.
2011: Christiane A Voit; Alexander M M Eggermont; Martina Kron; Gregor Schäfer-Hesterberg; Alfred Schoengen; Wolfram Sterry; Jens Ulrich; Alexander C J van Akkooi; Juergen Rademaker
Fine needle aspiration cytology of palpable and nonpalpable lymph nodes to detect metastatic melanoma.
Journal of the National Cancer Institute 2011;103(23):1771-7.
2011: Sebastiaan P Prens; A C J van Akkooi; Augustinus P T van der Ploeg; Albertus N van Geel; Cornelis A G M van Montfort; Johannes H W de Wilt; Alexander M M Eggermont; Cornelis Verhoef
Outcome after therapeutic lymph node dissection in patients with unknown primary melanoma site.
Annals of surgical oncology 2011;18(13):3586-92.
2011: Jill A van der Zee; C H J van Eijck; Herman van Dekken; Bilyana M Dicheva; Alexander M M Eggermont; Wim C J Hop; Gerben A Koning; Ann L B Seynhaeve; Timo L M ten Hagen
Angiogenesis: a prognostic determinant in pancreatic cancer?
European journal of cancer (Oxford, England : 1990) 2011;47(17):2576-84.
2011: Jan P Deroose; Alexander M M Eggermont; Albertus N van Geel; Jacobus W A Burger; Johannes H W de Wilt; Michael A Den Bakker; Cornelis Verhoef
Long-term results of tumor necrosis factor alpha- and melphalan-based isolated limb perfusion in locally advanced extremity soft tissue sarcomas.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(30):4036-44.
2011: Christiane A Voit; Gregor Schäfer-Hesterberg; Wolfram Sterry; Alexander J C van Akkooi; Alexander M M Eggermont
Multimodality approach to the sentinel node: an algorithm for the use of presentinel lymph node biopsy ultrasound (after lymphoscintigraphy) in conjunction with presentinel lymph node biopsy fine needle aspiration cytology.
Melanoma research 2011;21(5):450-6.
2011: Ninos Ayez; Jeroen de Jonge; Alexander M M Eggermont; Jan N M Ijzermans; Zarina S Lalmahomed; Anne E M van der Pool; Kees van Montfort; Yvonne Vergouwe; Cornelis Verhoef
Is the clinical risk score for patients with colorectal liver metastases still useable in the era of effective neoadjuvant chemotherapy?
Annals of surgical oncology 2011;18(10):2757-63.
2011: Alexander M M Eggermont
The European Academy of Cancer Sciences.
European journal of cancer (Oxford, England : 1990) 2011;47(14):2077-81.
2011: Alexander M M Eggermont
Therapeutic cancer vaccine development: will it ride the wave of new immunomodulatory agents?.
Cancer journal (Sudbury, Mass.) 2011;17(5):276.
2011: Alessandro Testori; Cornelis Verhoef; Alexander M M Eggermont; Mark B Faries; Hidde M Kroon; E Pennacchioli; John F Thompson
Treatment of melanoma metastases in a limb by isolated limb perfusion and isolated limb infusion.
Journal of surgical oncology 2011;104(4):397-404.
2011: Alexander M M Eggermont; Caroline Robert
New drugs in melanoma: it's a whole new world.
European journal of cancer (Oxford, England : 1990) 2011;47(14):2150-7.
2011: Marna G Bouwhuis; Sandra Collette; Els R de Groot; Alexander M M Eggermont; Wim H Kruit; Stefan Suciu; Antonius J G Swaak; Timo L M ten Hagen; Lucien A Aarden
Changes of ferritin and CRP levels in melanoma patients treated with adjuvant interferon-α (EORTC 18952) and prognostic value on treatment outcome.
Melanoma research 2011;21(4):344-51.
2011: Poulam M Patel; Cornelis J A Punt; Caroline Robert; Dirk Schadendorf; Alain Spatz; Stefan Suciu; John A Thompson; Uwe Trefzer; Sanjiv S Agarwala; Juergen Becker; Robert Conry; Neville Davidson; Reinhard Dummer; Alexander M M Eggermont; Kristel Engelen; Wen-Jen Hwu; Ulrich Keilholz; Wim H Kruit; Laurent Mortier
Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032).
European journal of cancer (Oxford, England : 1990) 2011;47(10):1476-83.
2011: Paul B Chapman; Brigitte Dreno; Reinhard Dummer; Alexander M M Eggermont; Keith T Flaherty; Claus Garbe; John B Haanen; Axel Hauschild; David Hogg; Jeannie Hou; Thomas Jouary; John M Kirkwood; James Larkin; Celeste Lebbe; Richard J Lee; Jiang Li; Paul Lorigan; Michele Maio; Betty Nelson; Keith Nolop; Steven J O'Day; Antoni Ribas; Caroline Robert; Dirk Schadendorf; Jeffrey A Sosman; Alessandro Testori; Grant A McArthur; Paolo Ascierto
Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
The New England journal of medicine 2011;364(26):2507-16.
2011: Augustinus P T van der Ploeg; A C J van Akkooi; Piotr Rutkowski; Zbigniew I Nowecki; Wanda Michej; Angana Mitra; Julia A Newton-Bishop; Martin Cook; Iris M C van der Ploeg; Omgo E Nieweg; Mari F C M van den Hout; Paul A M van Leeuwen; Christiane A Voit; Francesco Cataldo; Alessandro Testori; Caroline Robert; Harald J Hoekstra; Cornelis Verhoef; A Spatz; Alexander M M Eggermont
Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(16):2206-14.
2011: Alan Spatz; Alexander M M Eggermont
Melanoma--the pieces of the puzzle finally start coming together! Preface.
Molecular oncology 2011;5(2):113-5.
2011: Marna G Bouwhuis; Timo L M ten Hagen; Alexander M M Eggermont
Immunologic functions as prognostic indicators in melanoma.
Molecular oncology 2011;5(2):183-9.
2011: Philippe Autier; Jean-François Doré; Alexander M M Eggermont; Jan W Coebergh
Epidemiological evidence that UVA radiation is involved in the genesis of cutaneous melanoma.
Current opinion in oncology 2011;23(2):189-96.
2011: Arjen Joosse; Esther de Vries; Renate Eckel; Tamar Nijsten; Alexander M M Eggermont; Dieter Hölzel; Jan Willem W Coebergh; Jutta Engel
Gender differences in melanoma survival: female patients have a decreased risk of metastasis.
The Journal of investigative dermatology 2011;131(3):719-26.
2011: Jan P Deroose; Jacobus W A Burger; Albertus N van Geel; Michael A Den Bakker; Johannes S de Jong; Alexander M M Eggermont; Cornelis Verhoef
Radiotherapy for soft tissue sarcomas after isolated limb perfusion and surgical resection: essential for local control in all patients?
Annals of surgical oncology 2011;18(2):321-7.
2011: Menno van Lummel; Wim J van Blitterswijk; Stefan R Vink; Robert Jan Veldman; Martin A van der Valk; Debby Schipper; Bilyana M Dicheva; Alexander M M Eggermont; Timo L M ten Hagen; Marcel Verheij; Gerben A Koning
Enriching lipid nanovesicles with short-chain glucosylceramide improves doxorubicin delivery and efficacy in solid tumors.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2011;25(1):280-9.
2010: Christiane A Voit; Alexander C J van Akkooi; Alexander M M Eggermont
Role of ultrasound in the assessment of the sentinel node of melanoma patients.
AJR. American journal of roentgenology 2010;195(6):W474-5; author reply W476.
2010: Jill A van der Zee; Timo L M ten Hagen; Wim C J Hop; Herman van Dekken; Bilyana M Dicheva; Ann L B Seynhaeve; Gerben A Koning; Alexander M M Eggermont; C H J van Eijck
Differential expression and prognostic value of HMGA1 in pancreatic head and periampullary cancer.
European journal of cancer (Oxford, England : 1990) 2010;46(18):3393-9.
2010: Piotr Rutkowski; Zbigniew I Nowecki; Alexander C J van Akkooi; Jadwiga Kulik; Michej Wanda; Janusz A Siedlecki; Alexander M M Eggermont; Wlodzimierz Ruka
Multimarker reverse transcriptase-polymerase chain reaction assay in lymphatic drainage and sentinel node tumor burden.
Annals of surgical oncology 2010;17(12):3314-23.
2010: Alexander M M Eggermont; Alessandro Testori; Michele Maio; Caroline Robert
Anti-CTLA-4 antibody adjuvant therapy in melanoma.
Seminars in oncology 2010;37(5):455-9.
2010: Anne E M van der Pool; Zarina S Lalmahomed; Johannes H W de Wilt; Alexander M M Eggermont; Jan N M Ijzermans; Cornelis Verhoef
Trends in treatment for synchronous colorectal liver metastases: differences in outcome before and after 2000.
Journal of surgical oncology 2010;102(5):413-8.
2010: Axel Hoos; Alexander M M Eggermont; Sylvia Janetzki; F Stephen Hodi; Ramy Ibrahim; Aparna Anderson; Rachel Humphrey; Brent Blumenstein; Lloyd J Old; Jedd D Wolchok
Improved endpoints for cancer immunotherapy trials.
Journal of the National Cancer Institute 2010;102(18):1388-97.
2010: Augustinus P T van der Ploeg; A C J van Akkooi; P I M Schmitz; Senada Koljenovic; Cornelis Verhoef; Alexander M M Eggermont
EORTC Melanoma Group sentinel node protocol identifies high rate of submicrometastases according to Rotterdam Criteria.
European journal of cancer (Oxford, England : 1990) 2010;46(13):2414-21.
2010: Christiane A Voit; Alexander J C van Akkooi; Gregor Schäfer-Hesterberg; Wolfram Sterry; Alexander M M Eggermont
The value of preoperative ultrasound (after lymphoscintigraphy) in conjunction with pre-sentinel lymph node biopsy fine-needle aspiration outweighs the usage of ultrasound alone in conjunction with lymphoscintigraphy: the need for an algorithm.
Melanoma research 2010;20(4):357-9.
2010: A C J van Akkooi; Cornelis Verhoef; Alexander M M Eggermont
Importance of tumor load in the sentinel node in melanoma: clinical dilemmas.
Nature reviews. Clinical oncology 2010;7(8):446-54.
2010: Gerben A Koning; Alexander M M Eggermont; Lars H Lindner; Timo L M ten Hagen
Hyperthermia and thermosensitive liposomes for improved delivery of chemotherapeutic drugs to solid tumors.
Pharmaceutical research 2010;27(8):1750-4.
2010: Arjen Joosse; Esther de Vries; Casper H van Eijck; Alexander M M Eggermont; Tamar Nijsten; Jan Willem W Coebergh
Reactive oxygen species and melanoma: an explanation for gender differences in survival?
Pigment cell & melanoma research 2010;23(3):352-64.
2010: Marna G Bouwhuis; Stefan Suciu; Alessandro Testori; Wim H J Kruit; François Salès; Poulam Patel; Cornelis J A Punt; mario santinami; A Spatz; Timo L M ten Hagen; Alexander M M Eggermont
Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: prognostic significance of autoantibodies--EORTC 18991.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(14):2460-6.
2010: Alan Spatz; Gerald Batist; Alexander M M Eggermont
The biology behind prognostic factors of cutaneous melanoma.
Current opinion in oncology 2010;22(3):163-8.
2010: A C J van Akkooi; Christiane A Voit; Cornelis Verhoef; Alexander M M Eggermont
New developments in sentinel node staging in melanoma: controversies and alternatives.
Current opinion in oncology 2010;22(3):169-77.
2010: Li Li; Timo L M ten Hagen; Debby Schipper; Tom M Wijnberg; Gerard C van Rhoon; Alexander M M Eggermont; Lars H Lindner; Gerben A Koning
Triggered content release from optimized stealth thermosensitive liposomes using mild hyperthermia.
Journal of controlled release : official journal of the Controlled Release Society 2010;143(2):274-9.
2010: James L Abbruzzese; Alexander M M Eggermont; Eric H Rubin
Introducing new strategies in...
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(5):1347.
2010: A E van der Pool; J H de Wilt; Z S Lalmahomed; Alexander M M Eggermont; Jan N M Ijzermans; C Verhoef
Optimizing the outcome of surgery in patients with rectal cancer and synchronous liver metastases.
The British journal of surgery 2010;97(3):383-90.
2010: Alexander M M Eggermont; Marna G Bouwhuis; Wim H J Kruit; Alessandro Testori; Timo L M ten Hagen; Antoine Yver; Christine Xu
Serum concentrations of pegylated interferon alpha-2b in patients with resected stage III melanoma receiving adjuvant pegylated interferon alpha-2b in a randomized phase III trial (EORTC 18991).
Cancer chemotherapy and pharmacology 2010;65(4):671-7.
2010: Christiane Voit; Alexander C J Van Akkooi; Gregor Schäfer-Hesterberg; Alfred Schoengen; Katharina Kowalczyk; Joachim C Roewert; Wolfram Sterry; Alexander M M Eggermont
Ultrasound morphology criteria predict metastatic disease of the sentinel nodes in patients with melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(5):847-52.
2010: Alexander C J van Akkooi; Christiane A Voit; Cornelis Verhoef; Alexander M M Eggermont
Potential cost-effectiveness of US-guided FNAC in melanoma patients as a primary procedure and in follow-up.
Annals of surgical oncology 2010;17(2):660-2; author reply 663-4.
2010: Marna G Bouwhuis; Andreas Gast; Adina Figl; Alexander M M Eggermont; Kari Hemminki; Dirk Schadendorf; Rajiv Kumar
Polymorphisms in the CD28/CTLA4/ICOS genes: role in malignant melanoma susceptibility and prognosis?
Cancer immunology, immunotherapy : CII 2010;59(2):303-12.
2010: Sergio Bracarda; Alexander M M Eggermont; Jan Samuelsson
Redefining the role of interferon in the treatment of malignant diseases.
European journal of cancer (Oxford, England : 1990) 2010;46(2):284-97.
2009: Alberto Fusi; Sandra Collette; Antonia Busse; Stefan Suciu; Anika Rietz; mario santinami; Wim H J Kruit; Alessandro Testori; Cornelis J A Punt; Angus G Dalgleish; Alan Spatz; Alexander M M Eggermont; Ulrich Keilholz
Circulating melanoma cells and distant metastasis-free survival in stage III melanoma patients with or without adjuvant interferon treatment (EORTC 18991 side study).
European journal of cancer (Oxford, England : 1990) 2009;45(18):3189-97.
2009: Alexander M M Eggermont
Immunostimulation versus immunosuppression after multiple vaccinations: the woes of therapeutic vaccine development.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(22):6745-7.
2009: A C J van Akkooi; A Spatz; Alexander M M Eggermont; Martin Mihm; Martin G Cook
Expert opinion in melanoma: the sentinel node; EORTC Melanoma Group recommendations on practical methodology of the measurement of the microanatomic location of metastases and metastatic tumour burden.
European journal of cancer (Oxford, England : 1990) 2009;45(16):2736-42.
2009: Christiane A Voit; Alexander C J van Akkooi; Gregor Schäfer-Hesterberg; Alfred Schoengen; Paul I M Schmitz; Wolfram Sterry; Alexander M M Eggermont
Rotterdam Criteria for sentinel node (SN) tumor burden and the accuracy of ultrasound (US)-guided fine-needle aspiration cytology (FNAC): can US-guided FNAC replace SN staging in patients with melanoma?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(30):4994-5000.
2009: Annette Hougaard Chakera; Birger Hesse; Zeynep Burak; James R Ballinger; Allan Britten; Corrado Caracò; Alistair Cochran; Martin G Cook; KT Drzewiecki; Richard Essner; Einat Even-Sapir; Alexander M M Eggermont; Tanja Gmeiner Stopar; Christian Ingvar; Martin C Mihm; Stanley W McCarthy; Nicola Mozzillo; Omgo E Nieweg; Richard A Scolyer; Hans Starz; John F Thompson; Giuseppe Trifirò; Giuseppe Viale; Sergi Vidal-Sicart; Roger Uren; Wendy Waddington; Arturo Chiti; Alain Spatz; Alessandro Testori
EANM-EORTC general recommendations for sentinel node diagnostics in melanoma.
European journal of nuclear medicine and molecular imaging 2009;36(10):1713-42.
2009: Durk Fekkes; Arthur R Van Gool; Marjolein Bannink; Stefan Sleijfer; Wim H J Kruit; Bronno van der Holt; Alexander M M Eggermont; Michiel W Hengeveld; Gerrit Stoter
Nitric oxide production and monoamine oxidase activity in cancer patients during interferon-alpha therapy.
Amino acids 2009;37(4):703-8.
2009: Alexander M M Eggermont
Therapeutic vaccines in solid tumours: can they be harmful?
European journal of cancer (Oxford, England : 1990) 2009;45(12):2087-90.
2009: Sanjiv S Agarwala; Ulrich Keilholz; Erard Gilles; Agop Y Bedikian; Jane Wu; Richard Kay; Cy A Stein; Loretta M Itri; Stefan Suciu; Alexander M M Eggermont
LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951).
European journal of cancer (Oxford, England : 1990) 2009;45(10):1807-14.
2009: Marna G Bouwhuis; Stefan Suciu; Sandra Collette; Steinar Aamdal; Wim H J Kruit; Lars Bastholt; Ulrika Stierner; François Salès; Poulam Patel; Cornelis J A Punt; Micaela Hernberg; Alain Spatz; Timo L M ten Hagen; Johan Hansson; Alexander M M Eggermont
Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon.
Journal of the National Cancer Institute 2009;101(12):869-77.
2009: Alexander M M Eggermont; Dirk Schadendorf
Melanoma and immunotherapy.
Hematology/oncology clinics of North America 2009;23(3):547-64, ix-x.
2009: Alexander M M Eggermont
Immunotherapy: Vaccine trials in melanoma -- time for reflection.
Nature reviews. Clinical oncology 2009;6(5):256-8.
2009: Anne E M van der Pool; Z S Lalmahomed; Johannes H W de Wilt; Alexander M M Eggermont; Jan M N Ijzermans; Cornelis Verhoef
Local treatment for recurrent colorectal hepatic metastases after partial hepatectomy.
Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2009;13(5):890-5.
2009: Cornelis Verhoef; Anne E M van der Pool; Joost J Nuyttens; Andre S T Planting; Alexander M M Eggermont; Johannes H W de Wilt
The "liver-first approach" for patients with locally advanced rectal cancer and synchronous liver metastases.
Diseases of the colon and rectum 2009;52(1):23-30.
2009: Dirk J Grünhagen; Johannes H W de Wilt; Albertus N van Geel; Cornelis Verhoef; Alexander M M Eggermont
Isolated limb perfusion with TNF-alpha and melphalan in locally advanced soft tissue sarcomas of the extremities.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 2009;179():257-70.
2008: Christiane A Voit; Gregor Schäfer-Hesterberg; Martina Kron; Alexander C J van Akkooi; Juergen Rademaker; Ansgar Lukowsky; Alfred Schoengen; Markus Schwürzer-Voit; Wolfram Sterry; Markus Krause; J Röwert-Huber; Alexander M M Eggermont
Impact of molecular staging methods in primary melanoma: reverse-transcriptase polymerase chain reaction (RT-PCR) of ultrasound-guided aspirate of the sentinel node does not improve diagnostic accuracy, but RT-PCR of peripheral blood does predict survival.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(35):5742-7.
2008: Arthur R Van Gool; Robert Verkerk; Durk Fekkes; Marjolein Bannink; Stefan Sleijfer; Wim H J Kruit; Bronno van der Holt; Simon Scharpé; Alexander M M Eggermont; Gerrit Stoter; Michiel W Hengeveld
Neurotoxic and neuroprotective metabolites of kynurenine in patients with renal cell carcinoma treated with interferon-alpha: course and relationship with psychiatric status.
Psychiatry and clinical neurosciences 2008;62(5):597-602.
2008: Cornelis Verhoef; Johannes H W de Wilt; Timo L M ten Hagen; Alexander M M Eggermont
Isolated hepatic perfusion for the treatment of liver tumors: sunset or sunrise?
Surgical oncology clinics of North America 2008;17(4):877-94, xi.
2008: Johannes H W de Wilt; Alexander C J van Akkooi; Cornelis Verhoef; Alexander M M Eggermont
Detection of melanoma micrometastases in sentinel nodes - the cons.
Surgical oncology 2008;17(3):175-81.
2008: Alexander M M Eggermont; Stefan Suciu; mario santinami; Alessandro Testori; Wim H J Kruit; Jeremy Marsden; Cornelis J A Punt; François Salès; Martin Gore; Rona Mackie; Zvonko Kusic; Reinhard Dummer; Axel Hauschild; Elena MUSAT; Alain Spatz; Ulrich Keilholz
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial.
Lancet 2008;372(9633):117-26.
2008: Amir Mearadji; Michael A Den Bakker; Albertus N van Geel; Alexander M M Eggermont; Stefan Sleijfer; Jaap Verweij; Johannes H W de Wilt; Cornelis Verhoef
Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis.
Anti-cancer drugs 2008;19(6):607-12.
2008: Alexander M M Eggermont; Christiane Voit
Management of melanoma: a European perspective.
Surgical oncology clinics of North America 2008;17(3):635-48, x.
2008: Maarten Vermaas; Joost J Nuyttens; Floris T J Ferenschild; Cornelis Verhoef; Alexander M M Eggermont; Johannes H W de Wilt
Reirradiation, surgery and IORT for recurrent rectal cancer in previously irradiated patients.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2008;87(3):357-60.
2008: Johannes H W de Wilt; Alexander M M Eggermont
When to perform surgery in stage IV melanoma patients?
Onkologie 2008;31(5):226-7.
2008: Timo L M ten Hagen; Alexander M M Eggermont
Laboratory models of regional chemotherapy.
International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 2008;24(3):291-9.
2008: Cornelis Verhoef; Johannes H W de Wilt; Flavia Brunstein; Andreas W K S Marinelli; Boudewijn van Etten; Maarten Vermaas; Gunther Guetens; Gert de Boeck; Ernst A de Bruijn; Alexander M M Eggermont
Isolated hypoxic hepatic perfusion with retrograde outflow in patients with irresectable liver metastases; a new simplified technique in isolated hepatic perfusion.
Annals of surgical oncology 2008;15(5):1367-74.
2008: Alexander C J van Akkooi; Johannes H W de Wilt; Christiane Voit; Cees Verhoef; Stefan Suciu; Alexander M M Eggermont
Sentinel lymph-node false positivity in melanoma.
Nature clinical practice. Oncology 2008;5(4):E2.
2008: Timo L M ten Hagen; Ann L B Seynhaeve; Alexander M M Eggermont
Tumor necrosis factor-mediated interactions between inflammatory response and tumor vascular bed.
Immunological reviews 2008;222():299-315.
2008: Marjolein Bannink; Wim H J Kruit; Arthur R Van Gool; Stefan Sleijfer; Bronno van der Holt; Alexander M M Eggermont; Gerrit Stoter; Michiel W Hengeveld
Interferon-alpha in oncology patients: fewer psychiatric side effects than anticipated.
Psychosomatics 2008;49(1):56-63.
2008: Ann L B Seynhaeve; Alexander M M Eggermont; Timo L M ten Hagen
TNF and manipulation of the tumor cell-stromal interface: "ways to make chemotherapy effective".
Frontiers in bioscience : a journal and virtual library 2008;13():3034-45.
2007: Alexander M M Eggermont; Martin Gore
Randomized adjuvant therapy trials in melanoma: surgical and systemic.
Seminars in oncology 2007;34(6):509-15.
2007: Cornelis Verhoef; Johannes H W de Wilt; Dirk J Grünhagen; Albertus N van Geel; Timo L M ten Hagen; Alexander M M Eggermont
Isolated limb perfusion with melphalan and TNF-alpha in the treatment of extremity sarcoma.
Current treatment options in oncology 2007;8(6):417-27.
2007: Ann L B Seynhaeve; Saske Hoving; Debby Schipper; Cindy E Vermeulen; Gisela aan de Wiel-Ambagtsheer; Sandra T van Tiel; Alexander M M Eggermont; Timo L M ten Hagen
Tumor necrosis factor alpha mediates homogeneous distribution of liposomes in murine melanoma that contributes to a better tumor response.
Cancer research 2007;67(19):9455-62.
2007: A C J van Akkooi; M G Bouwhuis; Johannes H W de Wilt; Mike Kliffen; P I M Schmitz; Alexander M M Eggermont
Multivariable analysis comparing outcome after sentinel node biopsy or therapeutic lymph node dissection in patients with melanoma.
The British journal of surgery 2007;94(10):1293-9.
2007: Maarten Vermaas; Martijn Gosselink; Floris T J Ferenschild; E van den Aardweg; H E Lont; H W P M Kemperman; Erwin van der Harst; G W M Tetteroo; R J Oostenbroek; Cees M Dijkhuis; Alexander M M Eggermont; Johannes H W de Wilt
Introduction of preoperative radiotherapy in the treatment of operable rectal cancer in the Southwest region of the Netherlands.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2007;33(7):862-7.
2007: M B E Menke-Plugmers; Rudi Tjong Joe Wai; Albertus N van Geel; Alexander M M Eggermont
[Oncoplastic surgery of the breast: a combination of oncological and plastic surgery].
Nederlands tijdschrift voor geneeskunde 2007;151(29):1623-7.
2007: Albertus N van Geel; Michael A Den Bakker; Wim J Kirkels; Simon Horenblas; Bin B R Kroon; Johannes H W de Wilt; Alexander M M Eggermont; Wolter J Mooi; Madelon N A van der Aa
Prognosis of primary mucosal penile melanoma: a series of 19 Dutch patients and 47 patients from the literature.
Urology 2007;70(1):143-7.
2007: Bruce Elliott; Richard A Scolyer; Stefan Suciu; Serge Lebecque; Donata Rimoldi; Oliver Gugerli; Elena MUSAT; Raghwa N Sharma; Danielle Lienard; Ulrich Keilholz; Alessandro Testori; Alexander M M Eggermont; Rona MacKie; Caroline Robert; Martin Cook; John F Thompson; Eric Angevin; Alain Spatz
Long-term protective effect of mature DC-LAMP+ dendritic cell accumulation in sentinel lymph nodes containing micrometastatic melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(13):3825-30.
2007: Albertus N van Geel; C van der Pol; Annelise Notenboom; Joost J Nuyttens; Alexander M M Eggermont; Veerle F M Surmont; Alex P W M Maat
[Long-term results of the multidisciplinary surgical treatment of non-small-cell bronchial carcinoma in the superior sulcus (Pancoast tumour): a retrospective study].
Nederlands tijdschrift voor geneeskunde 2007;151(25):1406-11.
2007: E de Vries; Saskia Houterman; M L G Janssen-Heijnen; Tamar Nijsten; S A M van de Schans; Alexander M M Eggermont; J W W Coebergh
Up-to-date survival estimates and historical trends of cutaneous malignant melanoma in the south-east of The Netherlands.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(6):1110-6.
2007: Maarten Vermaas; Floris T J Ferenschild; Cornelis Verhoef; Joost J Nuyttens; Andreas W K S Marinelli; Theo Wiggers; Wim J Kirkels; Alexander M M Eggermont; Johannes H W de Wilt
Total pelvic exenteration for primary locally advanced and locally recurrent rectal cancer.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2007;33(4):452-8.
2007: Henrik Schmidt; Stefan Suciu; Cornelis J A Punt; Martin Gore; Wim H J Kruit; Poulam Patel; Danielle Lienard; Hans von der Maase; Alexander M M Eggermont; Ulrich Keilholz
Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(12):1562-9.
2007: Ferdy J Lejeune; Alexander M M Eggermont
Hyperthermic isolated limb perfusion with tumor necrosis factor is a useful therapy for advanced melanoma of the limbs.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(11):1449-50; author reply 1450-1.
2007: Flavia Brunstein; Saske Hoving; Gisela aan de Wiel-Ambagtsheer; Ernst A de Bruijn; Gunther Guetens; Alexander M M Eggermont; Timo L M ten Hagen
Decreased response rates by the combination of histamine and IL-2 in melphalan-based isolated limb perfusion.
Cancer immunology, immunotherapy : CII 2007;56(4):573-80.
2007: Cecile T M Brekelmans; Madeleine M A Tilanus-Linthorst; Caroline Seynaeve; A vd Ouweland; Marian Menke-Pluymers; C C M Bartels; Mieke Kriege; Albertus N van Geel; Curt W Burger; Alexander M M Eggermont; Hanne Meijers-Heijboer; Jan G M Klijn
Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases.
European journal of cancer (Oxford, England : 1990) 2007;43(5):867-76.
2007: A C J van Akkooi; M G Bouwhuis; Albertus N van Geel; R Hoedemaker; Cornelis Verhoef; Dirk J Grunhagen; P I M Schmitz; Alexander M M Eggermont; Johannes H W de Wilt
Morbidity and prognosis after therapeutic lymph node dissections for malignant melanoma.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2007;33(1):102-8.
2007: Flavia Brunstein; Alexander M M Eggermont; Gisela aan de Wiel-Ambagtsheer; Sandra T van Tiel; Joost A P Rens; Timo L M ten Hagen
Synergistic antitumor effects of histamine plus melphalan in isolated hepatic perfusion for liver metastases.
Annals of surgical oncology 2007;14(2):795-801.
2007: Marjolein Bannink; Durk Fekkes; Arthur R Van Gool; Wim H J Kruit; Stefan Sleijfer; Bronno van der Holt; Alexander M M Eggermont; Gerrit Stoter; Michiel W Hengeveld
Interferon-alpha influences tryptophan metabolism without inducing psychiatric side effects.
Neuropsychobiology 2007;55(3-4):225-31.
2007: Durk Fekkes; Marjolein Bannink; Wim H J Kruit; Arthur R Van Gool; Paul G H Mulder; Stefan Sleijfer; Alexander M M Eggermont; Gerrit Stoter
Influence of pegylated interferon-alpha therapy on plasma levels of citrulline and arginine in melanoma patients.
Amino acids 2007;32(1):121-6.
2006: Flavia Brunstein; Joost A P Rens; Sandra T van Tiel; Alexander M M Eggermont; Timo L M ten Hagen
Histamine, a vasoactive agent with vascular disrupting potential, improves tumour response by enhancing local drug delivery.
British journal of cancer 2006;95(12):1663-9.
2006: Remco van Horssen; Niels Galjart; Joost A P Rens; Alexander M M Eggermont; Timo L M ten Hagen
Differential effects of matrix and growth factors on endothelial and fibroblast motility: application of a modified cell migration assay.
Journal of cellular biochemistry 2006;99(6):1536-52.
2006: Remco van Horssen; Joost A P Rens; Debby Schipper; Alexander M M Eggermont; Timo L M ten Hagen
EMAP-II facilitates TNF-R1 apoptotic signalling in endothelial cells and induces TRADD mobilization.
Apoptosis : an international journal on programmed cell death 2006;11(12):2137-45.
2006: I J M Han-Geurts; Albertus N van Geel; L van Doorn; Alexander M M Eggermont; Cornelis Verhoef
Aggressive angiomyxoma: multimodality treatments can avoid mutilating surgery.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2006;32(10):1217-21.
2006: Cornelis J A Punt; Stefan Suciu; M A Gore; J Koller; Wim H J Kruit; Jose Thomas; Poulam Patel; Danielle Lienard; Alexander M M Eggermont; Ulrich Keilholz
Chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha2b and interleukin-2 versus two cycles of dacarbazine followed by chemoimmunotherapy in patients with metastatic melanoma: a randomised phase II study of the European Organization for Research and Treatment of Cancer Melanoma Group.
European journal of cancer (Oxford, England : 1990) 2006;42(17):2991-5.
2006: A C J van Akkooi; Cornelis Verhoef; Albertus N van Geel; Mike Kliffen; Alexander M M Eggermont; Johannes H W de Wilt
Sentinel node biopsy for clear cell sarcoma.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2006;32(9):996-9.
2006: Alexander M M Eggermont
Reaching first base in the treatment of metastatic melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(29):4673-4.
2006: A C J van Akkooi; Johannes H W de Wilt; Cornelis Verhoef; P I M Schmitz; Albertus N van Geel; Alexander M M Eggermont; Mike Kliffen
Clinical relevance of melanoma micrometastases (<0.1 mm) in sentinel nodes: are these nodes to be considered negative?
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17(10):1578-85.
2006: Remco van Horssen; Alexander M M Eggermont; Timo L M ten Hagen
Endothelial monocyte-activating polypeptide-II and its functions in (patho)physiological processes.
Cytokine & growth factor reviews 2006;17(5):339-48.
2006: Remco van Horssen; Joost A P Rens; Flavia Brunstein; Veronique Guns; Marjon van Gils; Timo L M Ten Hagen; Alexander M M Eggermont
Intratumoural expression of TNF-R1 and EMAP-II in relation to response of patients treated with TNF-based isolated limb perfusion.
International journal of cancer. Journal international du cancer 2006;119(6):1481-90.
2006: Saske Hoving; Ann L B Seynhaeve; Sandra T van Tiel; Gisela aan de Wiel-Ambagtsheer; Ernst A de Bruijn; Alexander M M Eggermont; Timo L M ten Hagen
Early destruction of tumor vasculature in tumor necrosis factor-alpha-based isolated limb perfusion is responsible for tumor response.
Anti-cancer drugs 2006;17(8):949-59.
2006: Esther de Vries; Eva Steliarova-Foucher; A Spatz; E Ardanaz; Alexander M M Eggermont; Dorry Boll
Skin cancer incidence and survival in European children and adolescents (1978-1997). Report from the Automated Childhood Cancer Information System project.
European journal of cancer (Oxford, England : 1990) 2006;42(13):2170-82.
2006: Floris T J Ferenschild; Maarten Vermaas; Joost J Nuyttens; Wilfried J Graveland; Andreas W K S Marinelli; J R M van der Sijp; Theo Wiggers; Cornelis Verhoef; Alexander M M Eggermont; Johannes H W de Wilt
Value of intraoperative radiotherapy in locally advanced rectal cancer.
Diseases of the colon and rectum 2006;49(9):1257-65.
2006: A C J van Akkooi; Hannah D Golab-Schwarz; Alexander M M Eggermont; Albertus N van Geel
Isolated limb perfusion for an irresectable melanoma recurrence in a Jehovah's witness.
European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery 2006;30(2):408-10.
2006: Madeleine M A Tilanus-Linthorst; C Alves; Caroline Seynaeve; Marian Menke-Pluymers; Alexander M M Eggermont; Cecile T M Brekelmans
Contralateral recurrence and prognostic factors in familial non-BRCA1/2-associated breast cancer.
The British journal of surgery 2006;93(8):961-8.
2006: Maarten Vermaas; Cornelis Verhoef; Alexander M M Eggermont; Johannes H W de Wilt; Jan-Willem Kuiper
Utility of repeat radiofrequency ablation to provide long-term local control in recurrent rectal cancer.
Surgery 2006;140(1):120.
2006: Sandra L Wong; Donald L Morton; John F Thompson; jeffrey gershenwald; Stanley P L Leong; Douglas S Reintgen; Haim Gutman; Michael Sabel; Grant W Carlson; Kelly M McMasters; Douglas S Tyler; James S Goydos; Alexander M M Eggermont; Omgo E Nieweg; A Benedict Cosimi; Adam I Riker; Daniel G Coit
Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: a multi-institutional study.
Annals of surgical oncology 2006;13(6):809-16.
2006: AY de Kanter; M B E Menke-Pluijmers; SC Henzen-Logmans; Albertus N van Geel; C J H van Eijck; Theo Wiggers; Alexander M M Eggermont
Reasons for failure to identify positive sentinel nodes in breast cancer patients with significant nodal involvement.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2006;32(5):498-501.
2006: Timo L M ten Hagen; Alexander M M Eggermont
Changing the pathophysiology of solid tumours: the potential of TNF and other vasoactive agents.
International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 2006;22(3):241-6.
2006: Dirk J Grünhagen; Johannes H W de Wilt; Albertus N van Geel; Alexander M M Eggermont
Isolated limb perfusion for melanoma patients--a review of its indications and the role of tumour necrosis factor-alpha.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2006;32(4):371-80.
2006: Dirk J Grunhagen; Johannes H W de Wilt; Wilfried J Graveland; Cornelis Verhoef; Albertus N van Geel; Alexander M M Eggermont
Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma.
Cancer 2006;106(8):1776-84.
2006: Véronique Winnepenninckx; Vladimir Lazar; Stefan Michiels; Philippe Dessen; Marguerite Stas; Soledad R Alonso; Marie-Françoise Avril; Pablo L Ortiz-Romero; Thomas Robert; Ovidiu Balacescu; Alexander M M Eggermont; Gilbert Lenoir; Alain Sarasin; Thomas Tursz; Joost J van den Oord; Alain Spatz
Gene expression profiling of primary cutaneous melanoma and clinical outcome.
Journal of the National Cancer Institute 2006;98(7):472-82.
2006: Alexander M M Eggermont
Randomized trials in melanoma: an update.
Surgical oncology clinics of North America 2006;15(2):439-51.
2006: Remco van Horssen; Timo L M ten Hagen; Alexander M M Eggermont
TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility.
The oncologist 2006;11(4):397-408.
2006: AY de Kanter; M M Menke-Pluymers; M W J M Wouters; I Burgmans; Albertus N van Geel; Alexander M M Eggermont
5-Year follow-up of sentinel node negative breast cancer patients.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2006;32(3):282-6.
2006: Eva M Noorda; Bart C Vrouenraets; Omgo E Nieweg; AN van Geel; Alexander M M Eggermont; Bin B R Kroon
Repeat isolated limb perfusion with TNFalpha and melphalan for recurrent limb melanoma after failure of previous perfusion.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2006;32(3):318-24.
2006: Dirk J Grünhagen; Johannes H W de Wilt; Timo L M ten Hagen; Alexander M M Eggermont
Technology insight: Utility of TNF-alpha-based isolated limb perfusion to avoid amputation of irresectable tumors of the extremities.
Nature clinical practice. Oncology 2006;3(2):94-103.
2006: A C J van Akkooi; Johannes H W de Wilt; Cornelis Verhoef; Wilfried J Graveland; Albertus N van Geel; Mike Kliffen; Alexander M M Eggermont
High positive sentinel node identification rate by EORTC melanoma group protocol. Prognostic indicators of metastatic patterns after sentinel node biopsy in melanoma.
European journal of cancer (Oxford, England : 1990) 2006;42(3):372-80.
2006: Türkan Terkivatan; Mike Kliffen; Johannes H W de Wilt; Albertus N van Geel; Alexander M M Eggermont; Cornelis Verhoef
Giant solitary fibrous tumour of the liver.
World journal of surgical oncology 2006;4():81.
2006: Ann L B Seynhaeve; C E Vermeulen; Alexander M M Eggermont; Timo L M ten Hagen
Cytokines and vascular permeability: an in vitro study on human endothelial cells in relation to tumor necrosis factor-alpha-primed peripheral blood mononuclear cells.
Cell biochemistry and biophysics 2006;44(1):157-69.
2006: Dirk J Grunhagen; Johannes H W de Wilt; Wilfried J Graveland; Albertus N van Geel; Alexander M M Eggermont
The palliative value of tumor necrosis factor alpha-based isolated limb perfusion in patients with metastatic sarcoma and melanoma.
Cancer 2006;106(1):156-62.
2005: Marian Menke-Pluymers; Caroline Seynaeve; Albertus N van Geel; Jan G M Klijn; E Johanna Meijers-Heijboer; Alexander M M Eggermont
[Preventive surgical prcedures for inherited risk of breast cancer].
Nederlands tijdschrift voor geneeskunde 2005;149(48):2663-7.
2005: Wim H J Kruit; Heidi H van Ojik; Vincent G Brichard; Bernard Escudier; Thierry Dorval; Brigitte Dréno; Poulam Patel; Nicolas van Baren; Marie-Françoise Avril; Sophie Piperno; Amir Khammari; Marguerite Stas; Gerd Ritter; Bernard Lethé; Danièle Godelaine; Francis Brasseur; Yi Zhang; Pierre van der Bruggen; Thierry Boon; Alexander M M Eggermont; Marie Marchand
Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma.
International journal of cancer. Journal international du cancer 2005;117(4):596-604.
2005: A C J van Akkooi; Johannes H W de Wilt; Albertus N van Geel; Cornelis Verhoef; Alexander M M Eggermont
[Sentinel lymph node biopsy for melanoma: prognostic value and disadvantages in 300 patients].
Nederlands tijdschrift voor geneeskunde 2005;149(45):2538; author reply 2538-9.
2005: Floris T J Ferenschild; Maarten Vermaas; Stefan O P Hofer; Cornelis Verhoef; Alexander M M Eggermont; Johannes H W de Wilt
Salvage abdominoperineal resection and perineal wound healing in local recurrent or persistent anal cancer.
World journal of surgery 2005;29(11):1452-7.
2005: Dirk J Grünhagen; Johannes H W de Wilt; Albertus N van Geel; Wilfried J Graveland; Cornelis Verhoef; Alexander M M Eggermont
TNF dose reduction in isolated limb perfusion.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2005;31(9):1011-9.
2005: Maarten Vermaas; Floris T J Ferenschild; Stefan O P Hofer; Cornelis Verhoef; Alexander M M Eggermont; Johannes H W de Wilt
Primary and secondary reconstruction after surgery of the irradiated pelvis using a gracilis muscle flap transposition.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2005;31(9):1000-5.
2005: Marion van Vliet; Cornelis F van Dijke; Piotr A Wielopolski; Timo L M ten Hagen; Jifke F Veenland; Anda Preda; Antonius J Loeve; Alexander M M Eggermont; Gabriel P Krestin
MR angiography of tumor-related vasculature: from the clinic to the micro-environment.
Radiographics : a review publication of the Radiological Society of North America, Inc 2005;25 Suppl 1():S85-97; discussion S97-8.
2005: Alexander M M Eggermont; Stefan Suciu; Rona MacKie; Wlodzimierz Ruka; Alessandro Testori; Wim H J Kruit; Cornelis J A Punt; Michelle Delauney; François Sales; Gerard Groenewegen; Dirk J Ruiter; Izabella Jagiello; Konstantin Stoitchkov; Ulrich Keilholz; Danielle Lienard
Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.
Lancet 2005;366(9492):1189-96.
2005: Paola Queirolo; Mirko Acquati; John M Kirkwood; Alexander M M Eggermont; Andrea Rocca; Alessandro Testori
Update: current management issues in malignant melanoma.
Melanoma research 2005;15(5):319-24.
2005: Dirk J Grünhagen; Johannes H W de Wilt; Cornelis Verhoef; Albertus N van Geel; Alexander M M Eggermont
TNF-based isolated limb perfusion in unresectable extremity desmoid tumours.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2005;31(8):912-6.
2005: M G A van IJken; Boudewijn van Etten; Gunther Guetens; Ernst A de Bruijn; Timo L M ten Hagen; Theo Wiggers; Alexander M M Eggermont
Balloon catheter hypoxic pelvic perfusion with mitomycin C and melphalan for locally advanced tumours in the pelvic region: a phase I-II trial.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2005;31(8):897-904.
2005: M G A van IJken; Boudewijn van Etten; Flavia Brunstein; Timo L M ten Hagen; Gunther Guetens; Johannes H W de Wilt; Ernst A de Bruijn; Alexander M M Eggermont
Bio-chemotherapeutic strategies and the (dis) utility of hypoxic perfusion of liver, abdomen and pelvis using balloon catheter techniques.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2005;31(8):807-16.
2005: Ulrich Keilholz; Cornelis J A Punt; Martin Gore; Wim H J Kruit; Poulam Patel; Danielle Lienard; Jose Thomas; Thomas M Proebstle; Alexander Schmittel; Dirk Schadendorf; Thierry Velu; Sylvie Negrier; Ulrich Kleeberg; Frederic Lehman; Stefan Suciu; Alexander M M Eggermont
Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(27):6747-55.
2005: Esther de Vries; Mathieu Boniol; Gianluca Severi; Alexander M M Eggermont; Philippe Autier; Veronique Bataille; Jean-François Doré; Dorry Boll
Public awareness about risk factors could pose problems for case-control studies: the example of sunbed use and cutaneous melanoma.
European journal of cancer (Oxford, England : 1990) 2005;41(14):2150-4.
2005: R B Takkenberg; Bart C Vrouenraets; AN van Geel; Omgo E Nieweg; Eva M Noorda; Alexander M M Eggermont; Bin B R Kroon
Palliative isolated limb perfusion for advanced limb disease in stage IV melanoma patients.
Journal of surgical oncology 2005;91(2):107-11.
2005: Dirk J Grünhagen; Boudewijn van Etten; Flavia Brunstein; Wilfried J Graveland; Albertus N van Geel; Johannes H W de Wilt; Alexander M M Eggermont
Efficacy of repeat isolated limb perfusions with tumor necrosis factor alpha and melphalan for multiple in-transit metastases in patients with prior isolated limb perfusion failure.
Annals of surgical oncology 2005;12(8):609-15.
2005: Timothy M Pawlik; Merrick I Ross; John F Thompson; Alexander M M Eggermont; jeffrey gershenwald
The risk of in-transit melanoma metastasis depends on tumor biology and not the surgical approach to regional lymph nodes.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(21):4588-90.
2005: Flavia Brunstein; Ivan Dunshee de Abranches Oliveira Santos; lydia ferreira; Sandra T van Tiel; Alexander M M Eggermont; Timo L M ten Hagen
Histamine combined with melphalan in isolated limb perfusion for the treatment of locally advanced soft tissue sarcomas: preclinical studies in rats.
Acta cirúrgica brasileira / Sociedade Brasileira para Desenvolvimento Pesquisa em Cirurgia 2005;20(4):275-9.
2005: Madeleine M A Tilanus-Linthorst; Mieke Kriege; Carla Boetes; Wim C J Hop; Inge-Marie Obdeijn; Jan C Oosterwijk; Hans L Peterse; Harmine M Zonderland; Sybren Meijer; Alexander M M Eggermont; Harry J de Koning; Jan G M Klijn; Cecile T M Brekelmans
Hereditary breast cancer growth rates and its impact on screening policy.
European journal of cancer (Oxford, England : 1990) 2005;41(11):1610-7.
2005: Alexander M M Eggermont
Evolving imaging technology: contrast-enhanced Doppler ultrasound is early and rapid predictor of tumour response.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(7):995-6.
2005: Saske Hoving; Ann L B Seynhaeve; Sandra T van Tiel; Alexander M M Eggermont; Timo L M ten Hagen
Addition of low-dose tumor necrosis factor-alpha to systemic treatment with STEALTH liposomal doxorubicin (Doxil) improved anti-tumor activity in osteosarcoma-bearing rats.
Anti-cancer drugs 2005;16(6):667-74.
2005: Dirk J Grünhagen; Alexander M M Eggermont; Albertus N van Geel; Wilfried J Graveland; Johannes H W deWilt
Prognostic factors after cervical lymph node dissection for cutaneous melanoma metastases.
Melanoma research 2005;15(3):179-84.
2005: Dirk J Grünhagen; Flavia Brunstein; Wilfried J Graveland; Albertus N van Geel; Johannes H W de Wilt; Alexander M M Eggermont
Isolated limb perfusion with tumor necrosis factor and melphalan prevents amputation in patients with multiple sarcomas in arm or leg.
Annals of surgical oncology 2005;12(6):473-9.
2005: Saske Hoving; Flavia Brunstein; Gisela aan de Wiel-Ambagtsheer; Sandra T van Tiel; Gert de Boeck; Ernst A de Bruijn; Alexander M M Eggermont; Timo L M ten Hagen
Synergistic antitumor response of interleukin 2 with melphalan in isolated limb perfusion in soft tissue sarcoma-bearing rats.
Cancer research 2005;65(10):4300-8.
2005: TE Lans; Dirk J Grünhagen; Johannes H W de Wilt; Albertus N van Geel; Alexander M M Eggermont
Isolated limb perfusions with tumor necrosis factor and melphalan for locally recurrent soft tissue sarcoma in previously irradiated limbs.
Annals of surgical oncology 2005;12(5):406-11.
2005: Maarten Vermaas; Floris T J Ferenschild; Joost J Nuyttens; Andreas W K S Marinelli; Theo Wiggers; J R M van der Sijp; Cornelis Verhoef; Wilfried J Graveland; Alexander M M Eggermont; Johannes H W de Wilt
Preoperative radiotherapy improves outcome in recurrent rectal cancer.
Diseases of the colon and rectum 2005;48(5):918-28.
2005: Boudewijn van Etten; Alexander M M Eggermont; Sandra T van Tiel; Gisela Ambagtsheer; Johannes H W de Wilt; Timo L M ten Hagen
Gene therapy in in vivo isolated perfusion models.
Current gene therapy 2005;5(2):195-202.
2005: Saske Hoving; Sandra T van Tiel; Alexander M M Eggermont; Timo L M ten Hagen
Effect of low-dose tumor necrosis factor-alpha in combination with STEALTH liposomal cisplatin (SPI-077) on soft-tissue- and osteosarcoma-bearing rats.
Anticancer research 2005;25(2A):743-50.
2005: Yi Zhang; Zhaojun Sun; hugues nicolay; Ralf G Meyer; Nicolina Renkvist; Vincent Stroobant; Jurgen Corthals; Javier Carrasco; Alexander M M Eggermont; Marie Marchand; Kris Thielemans; Thomas Wölfel; Thierry Boon; Pierre van der Bruggen
Monitoring of anti-vaccine CD4 T cell frequencies in melanoma patients vaccinated with a MAGE-3 protein.
Journal of immunology (Baltimore, Md. : 1950) 2005;174(4):2404-11.
2005: M R Kapma; Bart C Vrouenraets; Omgo E Nieweg; AN van Geel; Eva M Noorda; Alexander M M Eggermont; Bin B R Kroon
Major amputation for intractable extremity melanoma after failure of isolated limb perfusion.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2005;31(1):95-9.
2005: Alexander M M Eggermont
Current status of interferon-alpha in the treatment of melanoma.
Cancer chemotherapy and biological response modifiers 2005;22():729-37.
2005: Alexander M M Eggermont
Reducing the need for sentinel node procedures by ultrasound examination of regional lymph nodes.
Annals of surgical oncology 2005;12(1):3-5.
2005: Marjolein Bannink; Wim H J Kruit; Arthur R Van Gool; Paul G H Mulder; Stefan Sleijfer; Alexander M M Eggermont; Gerrit Stoter; Durk Fekkes
Platelet MAO activity during treatment with pegylated interferon-alfa in melanoma patients.
Progress in neuro-psychopharmacology & biological psychiatry 2005;29(1):109-14.
2004: Dirk J Grünhagen; Flavia Brunstein; Wilfried J Graveland; Albertus N van Geel; Johannes H W de Wilt; Alexander M M Eggermont
One hundred consecutive isolated limb perfusions with TNF-alpha and melphalan in melanoma patients with multiple in-transit metastases.
Annals of surgery 2004;240(6):939-47; discussion 947-8.
2004: Anda Preda; Piotr A Wielopolski; Timo L M ten Hagen; Marion van Vliet; Jifke F Veenland; Gisela Ambagtsheer; Sandra T van Tiel; M W Vogel; Alexander M M Eggermont; Gabriel P Krestin; Cornelis F van Dijke
Dynamic contrast-enhanced MRI using macromolecular contrast media for monitoring the response to isolated limb perfusion in experimental soft-tissue sarcomas.
Magma (New York, N.Y.) 2004;17(3-6):296-302.
2004: Flavia Brunstein; Saske Hoving; Ann L B Seynhaeve; Sandra T van Tiel; Gunther Guetens; Ernst A de Bruijn; Alexander M M Eggermont; Timo L M ten Hagen
Synergistic antitumor activity of histamine plus melphalan in isolated limb perfusion: preclinical studies.
Journal of the National Cancer Institute 2004;96(21):1603-10.
2004: Eva M Noorda; Bart C Vrouenraets; Omgo E Nieweg; Bert N van Geel; Alexander M M Eggermont; Bin B R Kroon
Isolated limb perfusion for unresectable melanoma of the extremities.
Archives of surgery (Chicago, Ill. : 1960) 2004;139(11):1237-42.
2004: Boudewijn van Etten; Alexander M M Eggermont; Gisela Ambagtsheer; Sandra T van Tiel; Timo L M ten Hagen
Impaired neutralising antibody formation and high transduction efficacy after isolated hepatic perfusion with adenoviral vectors.
British journal of cancer 2004;91(8):1610-3.
2004: E de Vries; Freddie Bray; Alexander M M Eggermont; Dorry Boll
Monitoring stage-specific trends in melanoma incidence across Europe reveals the need for more complete information on diagnostic characteristics.
European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) 2004;13(5):387-95.
2004: Alexander M M Eggermont; John M Kirkwood
Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?
European journal of cancer (Oxford, England : 1990) 2004;40(12):1825-36.
2004: M G A van IJken; Ernst A de Bruijn; Timo L M ten Hagen; Gert de Boeck; C H J van Eijck; Alexander M M Eggermont
Balloon catheter hypoxic abdominal and pelvic perfusion with tumour necrosis factor-alpha, Melphalan and Mitomycin C: a pharmacokinetic study in pigs.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2004;30(6):699-707.
2004: M G A van IJken; Boudewijn van Etten; Gunther Guetens; Timo L M ten Hagen; Johannes Jeekel; Ernst A de Bruijn; Alexander M M Eggermont; C H J van Eijck
Balloon catheter hypoxic abdominal perfusion with Mitomycin C and Melphalan for locally advanced pancreatic cancer: a phase I-II trial.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2004;30(6):671-80.
2004: Boudewijn van Etten; Sandra T van Tiel; Gisela Ambagtsheer; Alexander M M Eggermont; Timo L M ten Hagen
Isolated limb perfusion based anti-p21ras gene therapy in a rat rhabdomyosarcoma.
Anticancer research 2004;24(4):2295-301.
2004: TE Lans; Remco van Horssen; Alexander M M Eggermont; Timo L M ten Hagen
Involvement of endothelial monocyte activating polypeptide II in tumor necrosis factor-alpha-based anti-cancer therapy.
Anticancer research 2004;24(4):2243-8.
2004: Arthur R Van Gool; Heidi H van Ojik; Wim H J Kruit; Paul G H Mulder; Durk Fekkes; Marjolein Bannink; S Scharpé; Gerrit Stoter; Alexander M M Eggermont; M Maes; R Verkerk
Serum activity of prolyl endopeptidase, but not of dipeptidyl peptidase IV, is decreased by immunotherapy with IFN-alpha in high-risk melanoma patients.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 2004;24(7):411-5.
2004: Arthur R Van Gool; Heidi H van Ojik; Wim H J Kruit; Marjolein Bannink; Paul G H Mulder; Alexander M M Eggermont; Gerrit Stoter; Durk Fekkes
Pegylated interferon-alpha2b treatment in melanoma patients: influence on amino acids, 5-hydroxyindolacetic acid and pteridine plasma concentrations.
Anti-cancer drugs 2004;15(6):587-91.
2004: Boudewijn van Etten; Flavia Brunstein; M G A van IJken; Andreas W K S Marinelli; Cornelis Verhoef; J R M van der Sijp; Gunther Guetens; Gert de Boeck; Ernst A de Bruijn; Johannes H W de Wilt; Alexander M M Eggermont
Isolated hypoxic hepatic perfusion with orthograde or retrograde flow in patients with irresectable liver metastases using percutaneous balloon catheter techniques: a phase I and II study.
Annals of surgical oncology 2004;11(6):598-605.
2004: Timo L M ten Hagen; Saske Hoving; Gisela Ambagtsheer; Sandra T van Tiel; Alexander M M Eggermont
Lack of efficacy of Doxil in TNF-alpha-based isolated limb perfusion in sarcoma-bearing rats.
British journal of cancer 2004;90(9):1830-2.
2004: Eva M Noorda; Bart Takkenberg; Bart C Vrouenraets; Omgo E Nieweg; Bert N van Geel; Alexander M M Eggermont; Guus A M Hart; Bin B R Kroon
Isolated limb perfusion prolongs the limb recurrence-free interval after several episodes of excisional surgery for locoregional recurrent melanoma.
Annals of surgical oncology 2004;11(5):491-9.
2004: Peter Brouckaert; Nozomi Takahashi; Sandra T van Tiel; Jeroen Hostens; Alexander M M Eggermont; Ann L B Seynhaeve; Walter Fiers; Timo L M ten Hagen
Tumor necrosis factor-alpha augmented tumor response in B16BL6 melanoma-bearing mice treated with stealth liposomal doxorubicin (Doxil) correlates with altered Doxil pharmacokinetics.
International journal of cancer. Journal international du cancer 2004;109(3):442-8.
2004: Johannes H W de Wilt; Boudewijn van Etten; Cornelis Verhoef; Alexander M M Eggermont
Isolated hepatic perfusion: experimental evidence and clinical utility.
The Surgical clinics of North America 2004;84(2):627-41.
2004: Ulrich Kleeberg; S Suciu; E B Bröcker; Dirk J Ruiter; C Chartier; D Liénard; J Marsden; Dirk Schadendorf; Alexander M M Eggermont
Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis.
European journal of cancer (Oxford, England : 1990) 2004;40(3):390-402.
2004: Alexander M M Eggermont; Flavia Brunstein; Dirk J Grünhagen; Timo L M ten Hagen
Regional treatment of metastasis: role of regional perfusion. State of the art isolated limb perfusion for limb salvage.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004;15 Suppl 4():iv107-12.
2004: Dirk J Grünhagen; Flavia Brunstein; Timo L M ten Hagen; Albertus N van Geel; Johannes H W de Wilt; Alexander M M Eggermont
TNF-based isolated limb perfusion: a decade of experience with antivascular therapy in the management of locally advanced extremity soft tissue sarcomas.
Cancer treatment and research 2004;120():65-79.
2004: Timo L M ten Hagen; Alexander M M Eggermont
Tumor vascular therapy with TNF: critical review on animal models.
Methods in molecular medicine 2004;98():227-46.
2003: Eva M Noorda; Bart C Vrouenraets; Omgo E Nieweg; AN van Geel; Alexander M M Eggermont; Bin B R Kroon
Prognostic factors for survival after isolated limb perfusion for malignant melanoma.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2003;29(10):916-21.
2003: Philippe Autier; Dorry Boll; Mathieu Boniol; Jean-François Dore; Esther de Vries; Alexander M M Eggermont
Management of melanoma patients: benefit of intense follow-up schedule is not demonstrated.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(19):3707; author reply 3707-8.
2003: Jan Hofland; Robert Tenbrinck; Alexander M M Eggermont; Casper H J Eijck; Diederik Gommers; Wilhelm Erdmann
Effects of simultaneous aortocaval occlusion on oxygen consumption in patients.
Clinical physiology and functional imaging 2003;23(5):275-81.
2003: Arthur R Van Gool; Durk Fekkes; Wim H J Kruit; Paul G H Mulder; Timo L M ten Hagen; Marjolein Bannink; Michael Maes; Alexander M M Eggermont
Serum amino acids, biopterin and neopterin during long-term immunotherapy with interferon-alpha in high-risk melanoma patients.
Psychiatry research 2003;119(1-2):125-32.
2003: Alexander M M Eggermont; Johannes H W de Wilt; Timo L M ten Hagen
Current uses of isolated limb perfusion in the clinic and a model system for new strategies.
The lancet oncology 2003;4(7):429-37.
2003: Martin G Cook; Margaret A Green; Brian Anderson; Alexander M M Eggermont; Dirk J Ruiter; Alain Spatz; Mark W Kissin; B W E M Powell
The development of optimal pathological assessment of sentinel lymph nodes for melanoma.
The Journal of pathology 2003;200(3):314-9.
2003: Esther de Vries; Leo J Schouten; Otto Visser; Alexander M M Eggermont; Dorry Boll
Rising trends in the incidence of and mortality from cutaneous melanoma in the Netherlands: a Northwest to Southeast gradient?
European journal of cancer (Oxford, England : 1990) 2003;39(10):1439-46.
2003: Yi Zhang; Pascal Chaux; Vincent Stroobant; Alexander M M Eggermont; Jurgen Corthals; Bernard Maillère; Kris Thielemans; Marie Marchand; Thierry Boon; Pierre van der Bruggen
A MAGE-3 peptide presented by HLA-DR1 to CD4+ T cells that were isolated from a melanoma patient vaccinated with a MAGE-3 protein.
Journal of immunology (Baltimore, Md. : 1950) 2003;171(1):219-25.
2003: Timo L M ten Hagen; Alexander M M Eggermont
Solid tumor therapy: manipulation of the vasculature with TNF.
Technology in cancer research & treatment 2003;2(3):195-203.
2003: Albertus N van Geel; Caroline M E Contant; Rudi Tjong Joe Wai; P I M Schmitz; Alexander M M Eggermont; Marian M E Menke-Pluijmers
Mastectomy by inverted drip incision and immediate reconstruction: data from 510 cases.
Annals of surgical oncology 2003;10(4):389-95.
2003: AY de Kanter; P P A M Arends; Alexander M M Eggermont; Theo Wiggers
Radiation protection for the sentinel node procedure in breast cancer.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2003;29(4):396-9.
2003: W A M Mellink; A M V Dulmen; Theo Wiggers; Peter Spreeuwenberg; Alexander M M Eggermont; Jozien M Bensing
Cancer patients seeking a second surgical opinion: results of a study on motives, needs, and expectations.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(8):1492-7.
2003: Alexander M M Eggermont; Albertus N van Geel; Johannes H W de Wilt; Timo L M ten Hagen
The role of isolated limb perfusion for melanoma confined to the extremities.
The Surgical clinics of North America 2003;83(2):371-84, ix.
2003: Jan Hofland; Robert Tenbrinck; C H J van Eijck; Alexander M M Eggermont; Diederik Gommers; Wilhelm Erdmann
Comparison of closed circuit and Fick-derived oxygen consumption in patients undergoing simultaneous aortocaval occlusion.
Anaesthesia 2003;58(4):377-84.
2003: Mark R de Vries; Timo L M ten Hagen; Andreas W K S Marinelli; Alexander M M Eggermont
Tumor necrosis factor and isolated hepatic perfusion: from preclinical tumor models to clinical studies.
Anticancer research 2003;23(2C):1811-23.
2003: Alexander M M Eggermont; Timo L M ten Hagen
Tumor necrosis factor-based isolated limb perfusion for soft tissue sarcoma and melanoma: ten years of successful antivascular therapy.
Current oncology reports 2003;5(2):79-80.
2003: Arthur R Van Gool; Wim H J Kruit; Frederike K Engels; Gerrit Stoter; Marjolein Bannink; Alexander M M Eggermont
Neuropsychiatric side effects of interferon-alfa therapy.
Pharmacy world & science : PWS 2003;25(1):11-20.
2003: Boudewijn van Etten; Mark R de Vries; M G A van IJken; TE Lans; Gunther Guetens; Gisela Ambagtsheer; Sandra T van Tiel; Gert de Boeck; Ernst A de Bruijn; Alexander M M Eggermont; Timo L M ten Hagen
Degree of tumour vascularity correlates with drug accumulation and tumour response upon TNF-alpha-based isolated hepatic perfusion.
British journal of cancer 2003;88(2):314-9.
2003: Albert N Van Geel; Alexander M M Eggermont; Patrick E J Hanssens; P I M Schmitz
Factors Influencing Prognosis After Initial Inadequate Excision (IIE) for Soft Tissue Sarcoma.
Sarcoma 2003;7(3-4):159-65.
2003: Jan Hofland; Robert Tenbrinck; Alexander M M Eggermont; Wilhelm Erdmann
Comparison of the influence of xenon vs. isoflurane on ventilation-perfusion relationships in patients undergoing simultaneous aortocaval occlusion.
Advances in experimental medicine and biology 2003;540():61-9.
2003: Alexander M M Eggermont; Cornelis J A Punt
Does adjuvant systemic therapy with interferon-alpha for stage II-III melanoma prolong survival?
American journal of clinical dermatology 2003;4(8):531-6.
2003: Boudewijn van Etten; Albertus N van Geel; Johannes H W de Wilt; Alexander M M Eggermont
Fifty tumor necrosis factor-based isolated limb perfusions for limb salvage in patients older than 75 years with limb-threatening soft tissue sarcomas and other extremity tumors.
Annals of surgical oncology 2003;10(1):32-7.
2003: Marie Marchand; Cornelis J A Punt; Steinar Aamdal; Bernard Escudier; Wim H J Kruit; U Keilholz; L Håkansson; Nicolas van Baren; Yves Humblet; P Mulders; M-F Avril; Alexander M M Eggermont; C Scheibenbogen; J Uiters; Jantien Wanders; M Delire; Thierry Boon; Gerrit Stoter
Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report.
European journal of cancer (Oxford, England : 1990) 2003;39(1):70-7.
2002: TE Lans; Johannes H W de Wilt; Albertus N van Geel; Alexander M M Eggermont
Isolated limb perfusion with tumor necrosis factor and melphalan for nonresectable sSewart-Treves lymphangiosarcoma.
Annals of surgical oncology 2002;9(10):1004-9.
2002: Eva M Noorda; Bart C Vrouenraets; Omgo E Nieweg; AN van Geel; Alexander M M Eggermont; Bin B R Kroon
Safety and efficacy of isolated limb perfusion in elderly melanoma patients.
Annals of surgical oncology 2002;9(10):968-74.
2002: Madeleine M A Tilanus-Linthorst; Leon C Verhoog; Inge-Marie Obdeijn; Karina C M Bartels; Marian Menke-Pluymers; Alexander M M Eggermont; Jan G M Klijn; Hanne Meijers-Heijboer; Theo Van der Kwast; Cecile T M Brekelmans
A BRCA1/2 mutation, high breast density and prominent pushing margins of a tumor independently contribute to a frequent false-negative mammography.
International journal of cancer. Journal international du cancer 2002;102(1):91-5.
2002: Alexander M M Eggermont
Critical appraisal of IFN-alpha-based adjuvant therapy in stage II-III malignant melanoma.
Expert review of anticancer therapy 2002;2(5):563-9.
2002: TE Lans; Timo L M ten Hagen; Remco van Horssen; P C Wu; Sandra T van Tiel; Steven Libutti; H Richard Alexander; Alexander M M Eggermont
Improved antitumor response to isolated limb perfusion with tumor necrosis factor after upregulation of endothelial monocyte-activating polypeptide II in soft tissue sarcoma.
Annals of surgical oncology 2002;9(8):812-9.
2002: O E Nieweg; Alexander M M Eggermont; Bin B R Kroon
[Sentinel node biopsy in melanoma: some critical questions].
Nederlands tijdschrift voor geneeskunde 2002;146(38):1774-7.
2002: Caroline M E Contant; M B E Menke-Pluijmers; Caroline Seynaeve; E Johanna Meijers-Heijboer; Jan G M Klijn; Leon C Verhoog; R Tjong Joe Wai; Alexander M M Eggermont; Albertus N van Geel
Clinical experience of prophylactic mastectomy followed by immediate breast reconstruction in women at hereditary risk of breast cancer (HB(O)C) or a proven BRCA1 and BRCA2 germ-line mutation.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2002;28(6):627-32.
2002: E De Vries; J F Doré; P Autier; Alexander M M Eggermont; Dorry Boll
Patients' perception of the cause of their melanoma differs from that of epidemiologists.
The British journal of dermatology 2002;147(2):388-9.
2002: Alexander M M Eggermont; Martin Gore
European approach to adjuvant treatment of intermediate- and high-risk malignant melanoma.
Seminars in oncology 2002;29(4):382-8.
2002: Ulrich Keilholz; Peter Martus; Cornelis J A Punt; Wim H J Kruit; G Mooser; Dirk Schadendorf; D Liénard; R Dummer; J Koller; C Voit; Alexander M M Eggermont
Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments: second analysis of a randomised EORTC Melanoma Group trial comparing interferon-alpha2a (IFNalpha) and interleukin 2 (IL-2) with or without cisplatin.
European journal of cancer (Oxford, England : 1990) 2002;38(11):1501-11.
2002: Caroline M E Contant; A J G Swaak; A I M Obdeijn; B van der Holt; R Tjong Joe Wai; Albertus N van Geel; Alexander M M Eggermont
A prospective study on silicone breast implants and the silicone-related symptom complex.
Clinical rheumatology 2002;21(3):215-9.
2002: Ann L B Seynhaeve; Johannes H W de Wilt; Sandra T van Tiel; Alexander M M Eggermont; Timo L M ten Hagen
Isolated limb perfusion with actinomycin D and TNF-alpha results in improved tumour response in soft-tissue sarcoma-bearing rats but is accompanied by severe local toxicity.
British journal of cancer 2002;86(7):1174-9.
2002: TC Stam; A J G Swaak; Wim H J Kruit; Alexander M M Eggermont
Regulation of ferritin: a specific role for interferon-alpha (IFN-alpha)? The acute phase response in patients treated with IFN-alpha-2b.
European journal of clinical investigation 2002;32 Suppl 1():79-83.
2002: Alexander M M Eggermont
European approach to the treatment of malignant melanoma.
Current opinion in oncology 2002;14(2):205-11.
2002: Alexander M M Eggermont; Ulrich Keilholz; Philippe Autier; Dirk J Ruiter; F Lehmann; Danielle Lienard
The EORTC Melanoma Group: a comprehensive melanoma research programme by clinicians and scientists. European Organisation for Research and Treatment of Cancer.
European journal of cancer (Oxford, England : 1990) 2002;38 Suppl 4():S114-9.
2002: Timo L M ten Hagen; Alexander M M Eggermont
Manipulation of the tumour-associated vasculature to improve tumour therapy.
Journal of liposome research 2002;12(1-2):149-54.
2002: Jan Hofland; Robert Tenbrinck; M G A van IJken; C H J van Eijck; Alexander M M Eggermont; Wilhelm Erdmann
Cardiovascular effects of simultaneous occlusion of the inferior vena cava and aorta in patients treated with hypoxic abdominal perfusion for chemotherapy.
British journal of anaesthesia 2002;88(2):193-8.
2002: Boudewijn van Etten; Timo L M ten Hagen; Mark R de Vries; Gisela Ambagtsheer; T Huet; Alexander M M Eggermont
Prerequisites for effective adenovirus mediated gene therapy of colorectal liver metastases in the rat using an intracellular neutralizing antibody fragment to p21-Ras.
British journal of cancer 2002;86(3):436-42.
2002: Alexander H van der Veen; Timo L M ten Hagen; Ann L B Seynhaeve; Alexander M M Eggermont
Lack of cell-cycle specific effects of tumor necrosis factor-alpha on tumor cells in vitro: implications for combination tumor therapy with doxorubicin.
Cancer investigation 2002;20(4):499-508.
2002: Timo L M ten Hagen; Ann L B Seynhaeve; Sandra T van Tiel; Dirk J Ruiter; Alexander M M Eggermont
Pegylated liposomal tumor necrosis factor-alpha results in reduced toxicity and synergistic antitumor activity after systemic administration in combination with liposomal doxorubicin (Doxil) in soft tissue sarcoma-bearing rats.
International journal of cancer. Journal international du cancer 2002;97(1):115-20.
2001: Cornelis J A Punt; Alexander M M Eggermont
Adjuvant interferon-alpha for melanoma revisited: news from old and new studies.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12(12):1663-6.
2001: G Ghanem; B Loir; Renato Morandini; François Sales; Danielle Lienard; Alexander M M Eggermont; Ferdy Lejeune
On the release and half-life of S100B protein in the peripheral blood of melanoma patients.
International journal of cancer. Journal international du cancer 2001;94(4):586-90.
2001: Alexander M M Eggermont; H Newell
Translational research in clinical trials: the only way forward.
European journal of cancer (Oxford, England : 1990) 2001;37(16):1965.
2001: Alexander M M Eggermont
The role interferon-alpha in malignant melanoma remains to be defined.
European journal of cancer (Oxford, England : 1990) 2001;37(17):2147-53.
2001: Ferdy J Lejeune; B B Kroon; Franco Di Filippo; H J Hoekstra; mario santinami; Danielle Liénard; Alexander M M Eggermont
Isolated limb perfusion: the European experience.
Surgical oncology clinics of North America 2001;10(4):821-32, ix.
2001: Alexander M M Eggermont; Ulrich Keilholz; Alessandro Testori; M Cook; Danielle Lienard; Dirk J Ruiter
The EORTC melanoma group translational research program on prognostic factors and ultrastaging in association with the adjuvant therapy trials in stage II and stage III melanoma. European Organization for Research and Treatment of Cancer.
Annals of surgical oncology 2001;8(9 Suppl):38S-40S.
2001: Alexander M M Eggermont; Timo L M ten Hagen
Isolated limb perfusion for extremity soft-tissue sarcomas, in-transit metastases, and other unresectable tumors: credits, debits, and future perspectives.
Current oncology reports 2001;3(4):359-67.
2001: Bart C Vrouenraets; Alexander M M Eggermont; Augustinus A M Hart; Joost M Klaase; AN van Geel; Omgo E Nieweg; Bin B R Kroon
Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2001;27(4):390-5.
2001: Johannes H W de Wilt; Abraham Bout; Alexander M M Eggermont; Sandra T van Tiel; MW De Vries; Timo L M ten Hagen; W K de Roos; Dinko Valerio; M E van der Kaaden
Adenovirus-mediated interleukin 3 beta gene transfer by isolated limb perfusion inhibits growth of limb sarcoma in rats.
Human gene therapy 2001;12(5):489-502.
2001: R Koelemij; Muriel A Hagenaars; N Geeske Ensink; Alexander M M Eggermont; Cornelis J H van de Velde; Gert Jan Fleuren; Peter Kuppen
Administration of BiMAb-retargeted T cells in a rat hepatic metastases colon tumour model results in T-cell tumour infiltration independent of the route of administration.
Scandinavian journal of immunology 2001;53(3):277-81.
2000: W K de Roos; Johannes H W de Wilt; M E van Der Kaaden; Eric Manusama; MW De Vries; Abraham Bout; Timo L M ten Hagen; Dinko Valerio; Alexander M M Eggermont
Isolated limb perfusion for local gene delivery: efficient and targeted adenovirus-mediated gene transfer into soft tissue sarcomas.
Annals of surgery 2000;232(6):814-21.
2000: Liesbeth E Jonges; KM Giezeman-Smits; Ronald L P van Vlierberghe; N Geeske Ensink; Muriel A Hagenaars; E Joly; Alexander M M Eggermont; Cornelis J H van de Velde; Gert Jan Fleuren; Peter Kuppen
NK cells modulate MHC class I expression on tumor cells and their susceptibility to lysis.
Immunobiology 2000;202(4):326-38.
2000: AY de Kanter; Albertus N van Geel; M A Paul; C H van Eijck; SC Henzen-Logmans; RH Kruyt; E P Krenning; Alexander M M Eggermont; Theo Wiggers
Controlled introduction of the sentinel node biopsy in breast cancer in a multi-centre setting: the role of a coordinator for quality control.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2000;26(7):652-6.
2000: Cilia M Ferrier; S Suciu; Winny L Van Geloof; huub straatman; Alexander M M Eggermont; Heimen Schraffordt Koops; B B Kroon; Ferdy J Lejeune; Ulrich Kleeberg; Goos N P van Muijen; Dirk J Ruiter
High tPA-expression in primary melanoma of the limb correlates with good prognosis.
British journal of cancer 2000;83(10):1351-9.
2000: Johannes H W de Wilt; Eric Manusama; Boudewijn van Etten; Sandra T van Tiel; A S Jorna; Ann L B Seynhaeve; Timo L M ten Hagen; Alexander M M Eggermont
Nitric oxide synthase inhibition results in synergistic anti-tumour activity with melphalan and tumour necrosis factor alpha-based isolated limb perfusions.
British journal of cancer 2000;83(9):1176-82.
2000: Timo L M ten Hagen; Alexander H van der Veen; PT Nooijen; Sandra T van Tiel; Ann L B Seynhaeve; Alexander M M Eggermont
Low-dose tumor necrosis factor-alpha augments antitumor activity of stealth liposomal doxorubicin (DOXIL) in soft tissue sarcoma-bearing rats.
International journal of cancer. Journal international du cancer 2000;87(6):829-37.
2000: Johannes H W de Wilt; Gen-Ichiro Soma; Timo L M ten Hagen; Junko Kanou; K Takagi; PT Nooijen; A L Seynhaevel; Alexander M M Eggermont
Synergistic antitumour effect of TNF-SAM2 with melphalan and doxorubicin in isolated limb perfusion in rats.
Anticancer research 2000;20(5B):3491-6.
2000: Alexander H van der Veen; Timo L M ten Hagen; Johannes H W de Wilt; M G A van IJken; Alexander M M Eggermont
An overview on the use of TNF-alpha: our experience with regional administration and developments towards new opportunities for systemic application.
Anticancer research 2000;20(5B):3467-74.
2000: Alexander M M Eggermont
TNF registered in Europe: does TNF get a second chance?
Journal of immunotherapy (Hagerstown, Md. : 1997) 2000;23(4):505-6.
2000: M G A van IJken; Boudewijn van Etten; Johannes H W de Wilt; Sandra T van Tiel; Timo L M ten Hagen; Alexander M M Eggermont
Tumor necrosis factor-alpha augments tumor effects in isolated hepatic perfusion with melphalan in a rat sarcoma model.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2000;23(4):449-55.
2000: Alexander M M Eggermont; M G A van IJken; Boudewijn van Etten; J R M van der Sijp; Timo L M ten Hagen; Theo Wiggers; M Oudkerk; Gert de Boeck; Ernst A de Bruijn
Isolated hypoxic hepatic perfusion (IHHP) using balloon catheter techniques: from laboratory to the clinic towards a percutaneous procedure.
Hepato-gastroenterology 2000;47(33):776-81.
2000: TC Stam; A J G Swaak; Mark R de Vries; Timo L M ten Hagen; Alexander M M Eggermont
Systemic toxicity and cytokine/acute phase protein levels in patients after isolated limb perfusion with tumor necrosis factor-alpha complicated by high leakage.
Annals of surgical oncology 2000;7(4):268-75.
2000: TC Stam; A J G Swaak; Wim H J Kruit; Gerrit Stoter; Alexander M M Eggermont
Intrapleural administration of tumour necrosis factor-alpha (TNFalpha) in patients with mesothelioma: cytokine patterns and acute-phase protein response.
European journal of clinical investigation 2000;30(4):336-43.
2000: Johannes H W de Wilt; Timo L M ten Hagen; Gert de Boeck; Sandra T van Tiel; Ernst A de Bruijn; Alexander M M Eggermont
Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion.
British journal of cancer 2000;82(5):1000-3.
2000: Alexander H van der Veen; Johannes H W de Wilt; Alexander M M Eggermont; Sandra T van Tiel; Ann L B Seynhaeve; Timo L M ten Hagen
TNF-alpha augments intratumoural concentrations of doxorubicin in TNF-alpha-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects.
British journal of cancer 2000;82(4):973-80.
2000: Ulrich Keilholz; Alexander M M Eggermont
The role of interleukin-2 in the management of stage IV melanoma: the EORTC melanoma cooperative group program.
The cancer journal from Scientific American 2000;6 Suppl 1():S99-103.
2000: Muriel A Hagenaars; R Koelemij; N Geeske Ensink; Jaap van Eendenburg; Ronald L P van Vlierberghe; Alexander M M Eggermont; Cornelis J H van de Velde; Gert Jan Fleuren; Peter Kuppen
The development of novel mouse monoclonal antibodies against the CC531 rat colon adenocarcinoma.
Clinical & experimental metastasis 2000;18(4):281-9.
2000: Muriel A Hagenaars; N Geeske Ensink; Per H Basse; Marianne Hokland; Ulf Nannmark; Alexander M M Eggermont; Cornelis J H van de Velde; Gert Jan Fleuren; Peter Kuppen
The microscopic anatomy of experimental rat CC531 colon tumour metastases: consequences for immunotherapy?
Clinical & experimental metastasis 2000;18(2):189-96.
2000: Alexander M M Eggermont
Adjuvant therapy of malignant melanoma and the role of sentinel node mapping.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 2000;157():178-89.
2000: Muriel A Hagenaars; N Geeske Ensink; Alexander M M Eggermont; Edo A van der Velde; Cornelis J H van de Velde; Gert Jan Fleuren; Peter Kuppen
Endogenous natural killer cells do not play a role in antitumor effects induced by interleukin-2 in a syngeneic rat colon tumor model.
Cancer immunology, immunotherapy : CII 2000;48(10):561-8.
1999: AY de Kanter; C H van Eijck; Albertus N van Geel; R H Kruijt; S C Henzen; M A Paul; Alexander M M Eggermont; Theo Wiggers
Multicentre study of ultrasonographically guided axillary node biopsy in patients with breast cancer.
The British journal of surgery 1999;86(11):1459-62.
1999: R Koelemij; Peter Kuppen; Cornelis J H van de Velde; Gert Jan Fleuren; Muriel A Hagenaars; Alexander M M Eggermont
Bispecific antibodies in cancer therapy, from the laboratory to the clinic.
Journal of immunotherapy (Hagerstown, Md. : 1997) 1999;22(6):514-24.
1999: Danielle Liénard; Alexander M M Eggermont; Heimen Schraffordt Koops; B Kroon; G Towse; S Hiemstra; P Schmitz; J Clarke; G Steinmann; F Rosenkaimer; Ferdy J Lejeune
Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study.
Melanoma research 1999;9(5):491-502.
1999: KM Giezeman-Smits; Arko Gorter; Ronald L P van Vlierberghe; J D v Eendenburg; Alexander M M Eggermont; Gert Jan Fleuren; Peter Kuppen
The regulatory role of CD45 on rat NK cells in target cell lysis.
Journal of immunology (Baltimore, Md. : 1950) 1999;163(1):71-6.
1999: Bart C Vrouenraets; Bin B R Kroon; A C Ogilvie; AN van Geel; Omgo E Nieweg; A J Swaak; Alexander M M Eggermont
Absence of severe systemic toxicity after leakage-controlled isolated limb perfusion with tumor necrosis factor-alpha and melphalan.
Annals of surgical oncology 1999;6(4):405-12.
1999: Mark R de Vries; IH Borel Rinkes; A J G Swaak; C E Hack; Cornelis J H van de Velde; Theo Wiggers; R A E M Tollenaar; Peter Kuppen; Alexander M M Eggermont
Acute-phase response patterns in isolated hepatic perfusion with tumour necrosis factor alpha (TNF-alpha) and melphalan in patients with colorectal liver metastases.
European journal of clinical investigation 1999;29(6):553-60.
1999: Bart C Vrouenraets; Guus A M Hart; Alexander M M Eggermont; Joost M Klaase; Bert N van Geel; Omgo E Nieweg; Bin B R Kroon
Relation between limb toxicity and treatment outcomes after isolated limb perfusion for recurrent melanoma.
Journal of the American College of Surgeons 1999;188(5):522-30.
1999: Johannes H W de Wilt; Eric Manusama; Sandra T van Tiel; M G A van IJken; Timo L M ten Hagen; Alexander M M Eggermont
Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats.
British journal of cancer 1999;80(1-2):161-6.
1999: TC Stam; Alexander M M Eggermont; A J G Swaak
Effects of tumour necrosis factor alpha and melphalan on the cytokine production of circulating T cells in patients with cancer.
European journal of clinical investigation 1999;29(3):256-63.
1999: Richard A Feelders; A J G Swaak; J A Romijn; Alexander M M Eggermont; ET Tielens; G Vreugdenhil; E Endert; HG van Eijk; Arie Berghout
Characteristics of recovery from the euthyroid sick syndrome induced by tumor necrosis factor alpha in cancer patients.
Metabolism: clinical and experimental 1999;48(3):324-9.
1999: AF Olieman; Danielle Liénard; Alexander M M Eggermont; Bin B R Kroon; Ferdy J Lejeune; Harald J Hoekstra; Heimen Schraffordt Koops
Hyperthermic isolated limb perfusion with tumor necrosis factor alpha, interferon gamma, and melphalan for locally advanced nonmelanoma skin tumors of the extremities: a multicenter study.
Archives of surgery (Chicago, Ill. : 1960) 1999;134(3):303-7.
1999: Pascal Chaux; Valérie Vantomme; Vincent Stroobant; Kris Thielemans; Jurgen Corthals; Rosalie M Luiten; Alexander M M Eggermont; Thierry Boon; Pierre van der Bruggen
Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes.
The Journal of experimental medicine 1999;189(5):767-78.
1999: Muriel A Hagenaars; N Geeske Ensink; Liesbeth E Jonges; William Chambers; Alexander M M Eggermont; Cornelis J H van de Velde; Gert Jan Fleuren; Peter Kuppen
The development of a bi-specific anti-CD161A x anti-tumor antibody for rat NK cell targeting.
Immunobiology 1999;200(1):31-48.
1999: Alexander H van der Veen; Ann L B Seynhaeve; J Breurs; PT Nooijen; Richard L Marquet; Alexander M M Eggermont
In vivo isolated kidney perfusion with tumour necrosis factor alpha (TNF-alpha) in tumour-bearing rats.
British journal of cancer 1999;79(3-4):433-9.
1999: Eric Manusama; Johannes H W de Wilt; Timo L M ten Hagen; Richard L Marquet; Alexander M M Eggermont
Toxicity and antitumor activity of interferon gamma alone and in combinations with TNFalpha and melphalan in isolated limb perfusion in the BN175 sarcoma tumor model in rats.
Oncology reports 1999;6(1):173-7.
1998: Muriel A Hagenaars; Sander Zwaveling; Peter Kuppen; N Geeske Ensink; Alexander M M Eggermont; Marianne Hokland; Per H Basse; Cornelis J H van de Velde; Gert Jan Fleuren; Ulf Nannmark
Characteristics of tumor infiltration by adoptively transferred and endogenous natural-killer cells in a syngeneic rat model: implications for the mechanism behind anti-tumor responses.
International journal of cancer. Journal international du cancer 1998;78(6):783-9.
1998: M G A van IJken; Ernst A de Bruijn; Gert de Boeck; Timo L M ten Hagen; J R M van der Sijp; Alexander M M Eggermont
Isolated hypoxic hepatic perfusion with tumor necrosis factor-alpha, melphalan, and mitomycin C using balloon catheter techniques: a pharmacokinetic study in pigs.
Annals of surgery 1998;228(6):763-70.
1998: Alexander H van der Veen; Alexander M M Eggermont; Ann L B Seynhaeve; Timo L M ten Hagen
Biodistribution and tumor localization of stealth liposomal tumor necrosis factor-alpha in soft tissue sarcoma bearing rats.
International journal of cancer. Journal international du cancer 1998;77(6):901-6.
1998: Alexander M M Eggermont
TNF alpha in isolated perfusion systems: success in the limb, developments for the liver credits, debits and future perspectives.
Anticancer research 1998;18(5D):3899-905.
1998: Heimen Schraffordt Koops; Maurizio Vaglini; S Suciu; Bin B R Kroon; J F Thompson; J Göhl; Alexander M M Eggermont; Franco Di Filippo; E T Krementz; D Ruiter; Ferdy J Lejeune
Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(9):2906-12.
1998: Eric Manusama; PT Nooijen; J Stavast; Johannes H W de Wilt; Richard L Marquet; Alexander M M Eggermont
Assessment of the role of neutrophils on the antitumor effect of TNFalpha in an in vivo isolated limb perfusion model in sarcoma-bearing brown Norway rats.
The Journal of surgical research 1998;78(2):169-75.
1998: Alexander M M Eggermont
Strategy of the EORTC-MCG trial programme for adjuvant treatment of moderate-risk and high-risk melanoma.
European journal of cancer (Oxford, England : 1990) 1998;34 Suppl 3():S22-6.
1998: HS Schraffordt Koops; Alexander M M Eggermont; D Liènard; Bin B R Kroon; Harald J Hoekstra; A N van Geel; Omgo E Nieweg; Ferdy J Lejeune
Hyperthermic isolated limb perfusion with tumour necrosis factor and melphalan as treatment of locally advanced or recurrent soft tissue sarcomas of the extremities.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 1998;48(1):1-4.
1998: Richard A Feelders; G Vreugdenhil; Alexander M M Eggermont; P A Kuiper-Kramer; HG van Eijk; A J G Swaak
Regulation of iron metabolism in the acute-phase response: interferon gamma and tumour necrosis factor alpha induce hypoferraemia, ferritin production and a decrease in circulating transferrin receptors in cancer patients.
European journal of clinical investigation 1998;28(7):520-7.
1998: Eric Manusama; PT Nooijen; Timo L M ten Hagen; Alexander H van der Veen; MW De Vries; Johannes H W de Wilt; M G A van IJken; Richard L Marquet; Alexander M M Eggermont
Tumor necrosis factor-alpha in isolated perfusion systems in the treatment of cancer: the Rotterdam preclinical-clinical program.
Seminars in surgical oncology 1998;14(3):232-7.
1998: HS Schraffordt Koops; Alexander M M Eggermont; Danielle Liénard; Bin B R Kroon; Harald J Hoekstra; A N Van Geel; Omgo E Nieweg; Ferdy J Lejeune
Hyperthermic isolated limb perfusion for the treatment of soft tissue sarcomas.
Seminars in surgical oncology 1998;14(3):210-4.
1998: F Lejeune; Danielle Liénard; Alexander M M Eggermont
Regional administration of recombinant tumour necrosis factor-alpha in cancer, with special reference to melanoma.
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 1998;9(3):211-8.
1998: W van de Vrie; R L Marquet; Gerrit Stoter; E A De Bruijn; Alexander M M Eggermont
In vivo model systems in P-glycoprotein-mediated multidrug resistance.
Critical reviews in clinical laboratory sciences 1998;35(1):1-57.
1998: KM Giezeman-Smits; Liesbeth E Jonges; William Chambers; C S Brisette-Storkus; Ronald L P van Vlierberghe; Jaap van Eendenburg; Alexander M M Eggermont; Gert Jan Fleuren; Peter Kuppen
Novel monoclonal antibodies against membrane structures that are preferentially expressed on IL-2-activated rat NK cells.
Journal of leukocyte biology 1998;63(2):209-15.
1998: Muriel A Hagenaars; N Geeske Ensink; R Koelemij; Per H Basse; Alexander M M Eggermont; Cornelis J H van de Velde; Gert Jan Fleuren; Peter Kuppen
Regional administration of natural killer cells in a rat hepatic metastasis model results in better tumor infiltration and anti-tumor response than systemic administration.
International journal of cancer. Journal international du cancer 1998;75(2):233-8.
1998: Mark R de Vries; IH Borel Rinkes; Cornelis J H van de Velde; Theo Wiggers; R A E M Tollenaar; Peter Kuppen; Alexander L Vahrmeijer; Alexander M M Eggermont
Isolated hepatic perfusion with tumor necrosis factor alpha and melphalan: experimental studies in pigs and phase I data from humans.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1998;147():107-19.
1997: Alexander M M Eggermont
Is limb amputation necessary for locally advanced soft tissue sarcomas? Contra.
European journal of cancer (Oxford, England : 1990) 1997;33(14):2298-300.
1997: J Gérain; Danielle Liénard; Sandro Pampallona; M Baumgartner; Curzio Rüegg; W A Buurman; Alexander M M Eggermont; F Lejeune
Systemic release of soluble TNF receptors after high-dose TNF in isolated limb perfusion.
Cytokine 1997;9(12):1034-42.
1997: KM Giezeman-Smits; Arko Gorter; J Fred Nagelkerke; Ronald L P van Vlierberghe; Jaap van Eendenburg; Alexander M M Eggermont; Gert Jan Fleuren; Peter Kuppen
Characterization of three new membrane structures on rat NK cells which are involved in activation of the lytic machinery.
Immunobiology 1997;197(5):429-43.
1997: Alexander M M Eggermont; HS Schraffordt Koops; J M Klausner; Danielle Liénard; B B Kroon; P M Schlag; G Ben-Ari; Ferdy J Lejeune
Isolation limb perfusion with tumor necrosis factor alpha and chemotherapy for advanced extremity soft tissue sarcomas.
Seminars in oncology 1997;24(5):547-55.
1997: Alexander M M Eggermont
The current EORTC Melanoma Cooperative Group adjuvant trial programme on malignant melanoma: prognosis versus efficacy, toxicity and costs.
Melanoma research 1997;7 Suppl 2():S127-31.
1997: Peter Kuppen; Liesbeth E Jonges; Cornelis J H van de Velde; Alexander L Vahrmeijer; R A E M Tollenaar; IH Borel Rinkes; Alexander M M Eggermont
Liver and tumour tissue concentrations of TNF-alpha in cancer patients treated with TNF-alpha and melphalan by isolated liver perfusion.
British journal of cancer 1997;75(10):1497-500.
1997: IH Borel Rinkes; Mark R de Vries; A M Jonker; T J Swaak; C E Hack; P T Nooyen; Theo Wiggers; Alexander M M Eggermont
Isolated hepatic perfusion in the pig with TNF-alpha with and without melphalan.
British journal of cancer 1997;75(10):1447-53.
1997: W Van de Vrie; R L Marquet; Alexander M M Eggermont
Cyclosporin A enhances locoregional metastasis of the CC531 rat colon tumour.
Journal of cancer research and clinical oncology 1997;123(1):21-4.
1996: P T Nooijen; Eric Manusama; Alexander M M Eggermont; Lia Schalkwijk; J Stavast; Richard L Marquet; Robert M W de Waal; Dirk J Ruiter
Synergistic effects of TNF-alpha and melphalan in an isolated limb perfusion model of rat sarcoma: a histopathological, immunohistochemical and electron microscopical study.
British journal of cancer 1996;74(12):1908-15.
1996: Alexander M M Eggermont; HS Schraffordt Koops; J M Klausner; Bin B R Kroon; P M Schlag; Danielle Liénard; Albertus N van Geel; Harald J Hoekstra; I Meller; Omgo E Nieweg; C Kettelhack; G Ben-Ari; J C Pector; Ferdy J Lejeune
Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience.
Annals of surgery 1996;224(6):756-64; discussion 764-5.
1996: E J Sonneveld; Bart C Vrouenraets; B N van Geel; Alexander M M Eggermont; Joost M Klaase; Omgo E Nieweg; JA van Dongen; Bin B R Kroon
Systemic toxicity after isolated limb perfusion with melphalan for melanoma.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 1996;22(5):521-7.
1996: Alexander M M Eggermont; HS Schraffordt Koops; Danielle Liénard; Bin B R Kroon; Albertus N van Geel; Harald J Hoekstra; Ferdy J Lejeune
Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(10):2653-65.
1996: Wim H J Kruit; Cornelis J A Punt; Swan Hoo Goey; P H M De Mulder; J W Gratama; Alexander M M Eggermont; Reinder L H Bolhuis; Gerrit Stoter
Dose efficacy study of two schedules of high-dose bolus administration of interleukin 2 and interferon alpha in metastatic melanoma.
British journal of cancer 1996;74(6):951-5.
1996: KM Giezeman-Smits; Peter Kuppen; N Geeske Ensink; Alexander M M Eggermont; F Stals; K Wonigeit; Gert Jan Fleuren
The role of MHC class I expression in rat NK cell-mediated lysis of syngeneic tumor cells and virus-infected cells.
Immunobiology 1996;195(3):286-99.
1996: W M Klop; Bart C Vrouenraets; B N van Geel; Alexander M M Eggermont; Joost M Klaase; Omgo E Nieweg; Bin B R Kroon
Repeat isolated limb perfusion with melphalan for recurrent melanoma of the limbs.
Journal of the American College of Surgeons 1996;182(6):467-72.
1996: Robert J van Ginkel; Harald J Hoekstra; Alexander M M Eggermont; E Pras; Heimen Schraffordt Koops
Isolated limb perfusion of an irradiated foot with tumor necrosis factor, interferon, and melphalan.
Archives of surgery (Chicago, Ill. : 1960) 1996;131(6):672-4.
1996: Eric Manusama; P T Nooijen; J Stavast; N M Durante; Richard L Marquet; Alexander M M Eggermont
Synergistic antitumour effect of recombinant human tumour necrosis factor alpha with melphalan in isolated limb perfusion in the rat.
The British journal of surgery 1996;83(4):551-5.
1996: Eric Manusama; J Stavast; N M Durante; Richard L Marquet; Alexander M M Eggermont
Isolated limb perfusion with TNF alpha and melphalan in a rat osteosarcoma model: a new anti-tumour approach.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 1996;22(2):152-7.
1996: Swan Hoo Goey; Alexander M M Eggermont; R Oskam; T Wiggers; Reinder L H Bolhuis; Gerrit Stoter
Prolonged continuous hepatic artery infusion with interleukin-2 in unresectable liver metastases of colorectal cancer: a phase IA-B study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996;7(3):317-9.
1996: P T Nooijen; Alexander M M Eggermont; Marcel M Verbeek; Lia Schalkwijk; W A Buurman; Robert M W de Waal; Dirk J Ruiter
Transient induction of E-selectin expression following TNF alpha-based isolated limb perfusion in melanoma and sarcoma patients is not tumor specific.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1996;19(1):33-44.
1996: H H van Ravenswaay Claasen; Alexander M M Eggermont
Intraperitoneal immunotherapy of cancer: a review of options for treatment.
Cancer treatment and research 1996;82():13-40.
1996: Alexander M M Eggermont
Treatment of melanoma in-transit metastases confined to the limb.
Cancer surveys 1996;26():335-49.
1996: W Van de Vrie; J H M Schellens; W J Loss; HJ Kolker; J Verwey; Gerrit Stoter; N M Durante; Alexander M M Eggermont
Modulation of multidrug resistance with dexniguldipine hydrochloride (B8509-035) in the CC531 rat colon carcinoma model.
Journal of cancer research and clinical oncology 1996;122(7):403-8.
1995: Swan Hoo Goey; Alexander M M Eggermont; Cornelis J A Punt; R Slingerland; J W Gratama; R Oosterom; R Oskam; Reinder L H Bolhuis; Gerrit Stoter
Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I-II study.
British journal of cancer 1995;72(5):1283-8.
1995: Silvana Canevari; G Stoter; F Arienti; Giorgio Bolis; MI Colnaghi; E M Di Re; Alexander M M Eggermont; Swan Hoo Goey; J W Gratama; C H Lamers
Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody.
Journal of the National Cancer Institute 1995;87(19):1463-9.
1995: N Renard; P T Nooijen; Lia Schalkwijk; Robert M W de Waal; Alexander M M Eggermont; Danielle Liénard; B B Kroon; Ferdy J Lejeune; Dirk J Ruiter
VWF release and platelet aggregation in human melanoma after perfusion with TNF alpha.
The Journal of pathology 1995;176(3):279-87.
1995: F Lejeune; Danielle Liénard; Alexander M M Eggermont; H Schraffordt Koops; F Rosenkaimer; J Gérain; Joost M Klaase; B Kroon; P Schmitz
[Efficacy of the tumor necrosis factor-alpha (rTNF-alpha) associated with interferon-gamma and chemotherapy in extracorporeal circulation in the limb in inoperable malignant melanoma, soft tissue sarcoma and epidermoid carcinoma. A 4-year experience].
Bulletin du cancer 1995;82(7):561-7.
1995: Alexander M M Eggermont; Eric Manusama; Timo L M ten Hagen
Regional application of TNF alpha in the treatment of cancer: a preclinical-clinical interactive program.
Journal of inflammation 1995;47(1-2):104-13.
1995: F Lejeune; Danielle Liénard; Alexander M M Eggermont; H Schraffordt Koops; F Rosenkaimer; J Gérain; Joost M Klaase; B Kroon; J Vanderveken; P Schmitz
Administration of high-dose tumor necrosis factor alpha by isolation perfusion of the limbs. Rationale and results.
The Journal of infusional chemotherapy 1995;5(2):73-81.
1995: Bart C Vrouenraets; Joost M Klaase; Bin B R Kroon; B N van Geel; Alexander M M Eggermont; H R Franklin
Long-term morbidity after regional isolated perfusion with melphalan for melanoma of the limbs. The influence of acute regional toxic reactions.
Archives of surgery (Chicago, Ill. : 1960) 1995;130(1):43-7.
1995: F Lejeune; Danielle Liénard; Alexander M M Eggermont; H Schraffordt Koops; B Kroon
[Value of isolation-perfusion of the limbs in melanomas and sarcomas].
Annales de chirurgie 1995;49(1):9-12.
1995: Joost M Klaase; Bin B R Kroon; Alexander M M Eggermont; A N van Geel; HS Schraffordt Koops; J Oldhoff; Danielle Liénard; F J Lejeune; R Berkel; H R Franklin
A retrospective comparative study evaluating the results of mild hyperthermic versus controlled normothermic perfusion for recurrent melanoma of the extremities.
European journal of cancer (Oxford, England : 1990) 1995;31A(1):58-63.
1994: Bart C Vrouenraets; Alexander M M Eggermont; Joost M Klaase; B N Van Geel; JA van Dongen; Bin B R Kroon
Long-term neuropathy after regional isolated perfusion with melphalan for melanoma of the limbs.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 1994;20(6):681-5.
1994: F Lejeune; Danielle Liénard; Alexander M M Eggermont; H Schraffordt Koops; F Rosenkaimer; J Gérain; Joost M Klaase; B Kroon; J Vanderveken; P Schmitz
Rationale for using TNF alpha and chemotherapy in regional therapy of melanoma.
Journal of cellular biochemistry 1994;56(1):52-61.
1994: F Lejeune; Danielle Liénard; Alexander M M Eggermont; H Schraffordt Koops; B Kroon; J Gérain; F Rosenkaimer; P Schmitz
Clinical experience with high-dose tumor necrosis factor alpha in regional therapy of advanced melanoma.
Circulatory shock 1994;43(4):191-7.
1994: Joost M Klaase; Bin B R Kroon; B N van Geel; Alexander M M Eggermont; H R Franklin; Guus A M Hart
Patient- and treatment-related factors associated with acute regional toxicity after isolated perfusion for melanoma of the extremities.
American journal of surgery 1994;167(6):618-20.
1994: N Renard; Danielle Liénard; Laurence Lespagnard; Alexander M M Eggermont; R Heimann; F Lejeune
Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumour necrosis factor alpha (rTNF alpha).
International journal of cancer. Journal international du cancer 1994;57(5):656-63.
1994: Joost M Klaase; Bin B R Kroon; A N van Geel; J van Wijk; H R Franklin; Alexander M M Eggermont; A A Hart
Limb recurrence-free interval and survival in patients with recurrent melanoma of the extremities treated with normothermic isolated perfusion.
Journal of the American College of Surgeons 1994;178(6):564-72.
1994: BA Kapteijn; Joost M Klaase; A N van Geel; Alexander M M Eggermont; Bin B R Kroon
Results of regional isolated perfusion for locally inoperable melanoma of the limbs.
Melanoma research 1994;4(2):135-8.
1994: Danielle Liénard; Alexander M M Eggermont; H Schraffordt Koops; B B Kroon; F Rosenkaimer; P Autier; Ferdy J Lejeune
Isolated perfusion of the limb with high-dose tumour necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma) and melphalan for melanoma stage III. Results of a multi-centre pilot study.
Melanoma research 1994;4 Suppl 1():21-6.
1994: Joost M Klaase; Bin B R Kroon; A N van Geel; Alexander M M Eggermont; H R Franklin; JA van Dongen
Is there an indication for a double perfusion schedule with melphalan for patients with recurrent melanoma of the limbs?
Melanoma research 1994;4 Suppl 1():13-6.
1994: Peter Kuppen; Per H Basse; Ronald H Goldfarb; Cornelis J H van de Velde; Gert Jan Fleuren; Alexander M M Eggermont
The infiltration of experimentally induced lung metastases of colon carcinoma CC531 by adoptively transferred interleukin-2-activated natural killer cells in Wag rats.
International journal of cancer. Journal international du cancer 1994;56(4):574-9.
1994: H H van Ravenswaay Claasen; Alexander M M Eggermont; Y A Nooyen; SO Warnaar; G J Fieuren
Immunotherapy in a human ovarian cancer xenograft model with two bispecific monoclonal antibodies: OV-TL 3/CD3 and OC/TR.
Gynecologic oncology 1994;52(2):199-206.
1994: Peter Kuppen; Alexander M M Eggermont; R B Quak; A Marinelli; Cornelis J H van de Velde; Gert Jan Fleuren
Soluble factors produced by macrophages/monocytes inhibit lymphokine-activated killer activity in rat splenocyte cultures.
Cancer immunology, immunotherapy : CII 1994;38(1):61-7.
1994: Joost M Klaase; Bin B R Kroon; A N van Geel; Alexander M M Eggermont; H R Franklin; A A Hart
Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion with melphalan.
Surgery 1994;115(1):39-45.
1994: W Van de Vrie; A M Jonker; R L Marquet; Alexander M M Eggermont
The chemosensitizer cyclosporin A enhances the toxic side-effects of doxorubicin in the rat.
Journal of cancer research and clinical oncology 1994;120(9):533-8.
1994: K M Smits; Peter Kuppen; Alexander M M Eggermont; T Tamatani; M Miyasaka; Gert Jan Fleuren
Rat interleukin-2-activated natural killer (A-NK) cell-mediated lysis is determined by the presence of CD18 on A-NK cells and the absence of major histocompatibility complex class I on target cells.
European journal of immunology 1994;24(1):171-5.
1993: W Van de Vrie; S A Van der Heyden; E E Gheuens; A M Bijma; E A De Bruijn; R L Marquet; AT van Oosterom; Alexander M M Eggermont
Drug resistance in rat colon cancer cell lines is associated with minor changes in susceptibility to cytotoxic cells.
Cancer immunology, immunotherapy : CII 1993;37(5):337-42.
1993: K M Smits; Peter Kuppen; Alexander M M Eggermont; Gert Jan Fleuren
Preincubation of tumor cells with the anti-(MHC) class I antibody OX18 enhances tumor cell lysis by interleukin-2-activated NK cells.
Transplantation proceedings 1993;25(5):2806-7.
1993: K M Smits; Peter Kuppen; S P Lazeroms; Alexander M M Eggermont; Gert Jan Fleuren
Major histocompatibility complex class I expression and sensitivity to interleukin-2 activated NK cell-mediated lysis of adenovirus-transformed baby rat kidney cells.
Transplantation proceedings 1993;25(5):2804-5.
1993: Joost M Klaase; Bin B R Kroon; A N van Geel; Alexander M M Eggermont; H R Franklin
Systemic leakage during isolated limb perfusion for melanoma.
The British journal of surgery 1993;80(9):1124-6.
1993: G D Beun; Cornelis J H van de Velde; Gert Jan Fleuren; Alexander M M Eggermont
T-cell retargeting using bispecific monoclonal antibodies in a rat colon carcinoma model: IV. Tumor neutralization in Winn type assays.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1993;14(1):11-5.
1993: Peter Kuppen; Alexander M M Eggermont; K M Smits; Jaap van Eendenburg; S P Lazeroms; Cornelis J H van de Velde; Gert Jan Fleuren
The development and purification of a bispecific antibody for lymphokine-activated killer cell targeting against the rat colon carcinoma CC531.
Cancer immunology, immunotherapy : CII 1993;36(6):403-8.
1993: Joost M Klaase; Bin B R Kroon; A N van Geel; Alexander M M Eggermont; H R Franklin; JA van Dongen
A retrospective comparative study evaluating the results of a single-perfusion versus double-perfusion schedule with melphalan in patients with recurrent melanoma of the lower limb.
Cancer 1993;71(10):2990-4.
1993: Wim H J Kruit; Reinder L H Bolhuis; Swan Hoo Goey; R L Jansen; Alexander M M Eggermont; D Batchelor; P I M Schmitz; G Stoter
Interleukin-2-induced thyroid dysfunction is correlated with treatment duration but not with tumor response.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(5):921-4.
1993: Bart C Vrouenraets; Bin B R Kroon; Joost M Klaase; B N Van Geel; Alexander M M Eggermont; H R Franklin
Adjuvant regional isolated perfusion with melphalan for patients with Clark V melanoma of the extremities.
Journal of surgical oncology 1993;52(4):249-54.
1993: Bart C Vrouenraets; Bin B R Kroon; Joost M Klaase; B N van Geel; Alexander M M Eggermont; Wolter J Mooi; JA van Dongen
Regional isolated perfusion with melphalan for patients with subungual melanoma.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 1993;19(1):37-42.
1993: Bin B R Kroon; Joost M Klaase; B N van Geel; Alexander M M Eggermont; H R Franklin; JA van Dongen
Results of a double perfusion schedule with melphalan in patients with melanoma of the lower limb.
European journal of cancer (Oxford, England : 1990) 1993;29A(3):325-8.
1993: W Van de Vrie; E E Gheuens; N M Durante; E A De Bruijn; R L Marquet; AT van Oosterom; Alexander M M Eggermont
In vitro and in vivo chemosensitizing effect of cyclosporin A on an intrinsic multidrug-resistant rat colon tumour.
Journal of cancer research and clinical oncology 1993;119(10):609-14.
1992: Joost M Klaase; Bin B R Kroon; A N van Geel; Alexander M M Eggermont; H R Franklin; JA van Dongen
The role of regional isolated perfusion in the eradication of melanoma micrometastases in the inguinal nodes: a comparison between an iliac and femoral perfusion procedure.
Melanoma research 1992;2(5-6):407-10.
1992: Peter Kuppen; A Marinelli; J A Camps; Ernest K J Pauwels; Cornelis J H van de Velde; Gert Jan Fleuren; Alexander M M Eggermont
Biodistribution of lymphokine-activated killer (LAK) cells in Wag rats after hepatic-artery or jugular-vein infusion.
International journal of cancer. Journal international du cancer 1992;52(2):266-70.
1992: Reinder L H Bolhuis; Cor H J Lamers; Swan Hoo Goey; Alexander M M Eggermont; J B Trimbos; G Stoter; A Lanzavecchia; E di Re; Silvia Miotti; Francesco Raspagliesi
Adoptive immunotherapy of ovarian carcinoma with bs-MAb-targeted lymphocytes: a multicenter study.
International journal of cancer. Supplement = Journal international du cancer. Supplement 1992;7():78-81.
1992: G Stoter; Swan Hoo Goey; D Batchelor; Alexander M M Eggermont; Cor H J Lamers; J W Gratama; Reinder L H Bolhuis
Treatment of disseminated renal cell cancer with combinations of interleukin-2, lymphokine-activated killer cells, and alpha-interferon.
Progress in clinical and biological research 1992;378():225-33.
1991: Wim H J Kruit; Swan Hoo Goey; J R Monson; R A Stahel; F Calabresi; R Mertelsmann; E E Holdener; Alexander M M Eggermont; Reinder L H Bolhuis; P H M De Mulder
Clinical experience with the combined use of recombinant interleukin-2 (IL2) and interferon alfa-2a (IFN alpha) in metastatic melanoma.
British journal of haematology 1991;79 Suppl 1():84-6.
1991: Peter Kuppen; Alexander M M Eggermont; A Marinelli; E de Heer; Cornelis J H van de Velde; Gert Jan Fleuren
Induction of lymphokine-activated killer activity in rat splenocyte cultures: the importance of 2-mercaptoethanol and indomethacin.
Cancer immunology, immunotherapy : CII 1991;33(1):28-32.
1990: L Bouwens; A Marinelli; Peter Kuppen; Alexander M M Eggermont; C J van de Velde; Eddie Wisse
Electron microscopic observations on the accumulation of large granular lymphocytes (pit cells) and Kupffer cells in the liver of rats treated with continuous infusion of interleukin-2.
Hepatology (Baltimore, Md.) 1990;12(6):1365-70.
1990: A Marinelli; Cornelis J H van de Velde; Peter Kuppen; H C Franken; J H Souverijn; Alexander M M Eggermont
A comparative study of isolated liver perfusion versus hepatic artery infusion with mitomycin C in rats.
British journal of cancer 1990;62(6):891-6.
1990: G Stoter; Swan Hoo Goey; Alexander M M Eggermont; R Slingerland; E Braakman; Cor H J Lamers; Reinder L H Bolhuis
Interleukin-2. The experience of the Rotterdam Cancer Institute; Daniel den Hoed Kliniek.
Biotherapy (Dordrecht, Netherlands) 1990;2(3):261-5.